WO2012086241A1 - 光学活性なジアザビシクロオクタン誘導体およびその製造法 - Google Patents
光学活性なジアザビシクロオクタン誘導体およびその製造法 Download PDFInfo
- Publication number
- WO2012086241A1 WO2012086241A1 PCT/JP2011/065001 JP2011065001W WO2012086241A1 WO 2012086241 A1 WO2012086241 A1 WO 2012086241A1 JP 2011065001 W JP2011065001 W JP 2011065001W WO 2012086241 A1 WO2012086241 A1 WO 2012086241A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diazabicyclo
- oxo
- octane
- formula
- benzyloxy
- Prior art date
Links
- 0 *[C@@](CC1)N(*)C[C@]1O Chemical compound *[C@@](CC1)N(*)C[C@]1O 0.000 description 5
- FCEIHZSFVFAQKP-WIHSUSGWSA-N CCCC(C1)C1OC([C@H](CCC(C1)=O)N1OC(c1ccccc1)=O)=O Chemical compound CCCC(C1)C1OC([C@H](CCC(C1)=O)N1OC(c1ccccc1)=O)=O FCEIHZSFVFAQKP-WIHSUSGWSA-N 0.000 description 1
- FCLIRSLCLMOJPU-DAFXYXGESA-N CCCC(C1)[I]1OC([C@H](CCC(C=S(C)(C)=O)=O)NOC(c1ccccc1)=O)=O Chemical compound CCCC(C1)[I]1OC([C@H](CCC(C=S(C)(C)=O)=O)NOC(c1ccccc1)=O)=O FCLIRSLCLMOJPU-DAFXYXGESA-N 0.000 description 1
- VVUANJGLDBXQCP-YVZMLIKISA-N CCCC(C1)[I]1OC([C@H](CC[C@@H](C1)O)N1OC(c1ccccc1)=O)=O Chemical compound CCCC(C1)[I]1OC([C@H](CC[C@@H](C1)O)N1OC(c1ccccc1)=O)=O VVUANJGLDBXQCP-YVZMLIKISA-N 0.000 description 1
- RSMCTEQNKRNFPX-JTQLQIEISA-N COC([C@H](CCC1=O)N1OC(c1ccccc1)=O)=O Chemical compound COC([C@H](CCC1=O)N1OC(c1ccccc1)=O)=O RSMCTEQNKRNFPX-JTQLQIEISA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- the present invention relates to an optically active diazabicyclooctane derivative represented by the following formula (F) useful as a pharmaceutical intermediate of a ⁇ -lactamase inhibitor, and a method for producing the same.
- R 1 represents CO 2 R, CO 2 M, or CONH 2
- R represents a methyl group, a tert-butyl group, an allyl group, a benzyl group, or 2,5-dioxopyrrolidine-1 -Represents an yl group
- M represents a hydrogen atom, an inorganic cation, or an organic cation
- R 2 represents a benzyl group or an allyl group.
- Penicillin and cephalosporin are the most widely and frequently used ⁇ -lactam antibacterial agents in the medical field.
- the most prominent resistance mechanism is the production of ⁇ -lactamases of class A, C and D with serine residues at the active center. These enzymes degrade ⁇ -lactam antibacterial agents and lead to inactivation of antibacterial activity.
- Class A ⁇ -lactamase has substrate specificity mainly for penicillin drugs
- class C ⁇ -lactamase mainly has substrate specificity for cephalosporins.
- Clavulanic acid, sulbactam, and tazobactam are known as commercially available ⁇ -lactamase inhibitors. These inhibitors are mainly effective against class A ⁇ -lactamase producing bacteria and are combined with penicillin antibacterial agents. ing. However, more than 250 types of ⁇ -lactamases have been reported to date, and in addition to the diffusion of class C ⁇ -lactamases and substrate-extended ⁇ -lactamases (ESBL) belonging to class A and D types. In addition, resistant bacteria that produce KPC-2, which belongs to class A type and degrades even carbapenem, which is the last fort of ⁇ -lactam antibacterial agents, have been regarded as a problem. Although the above-mentioned commercially available inhibitors are ineffective against these ⁇ -lactamases, there is a strong demand for the development of new inhibitors. However, although there are reports of potential inhibitors, Few.
- Example 1 of WO2009 / 091856A2 (Patent Document 3) and WO2010 / 126820A2 (Patent Document 4) show methods for producing derivatives having specific amide side chains.
- Patent Document 3 (2S, 5R) -6- (benzyloxy) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylic acid is used as a search intermediate. Only the chemical name of the acid is described.
- Patent Document 5 describes (2S, 5R) -6-hydroxy-7-oxo-1,6-diazabicyclo [3.2.1] octane.
- EP2135959A1 Patent Document 6
- the chemical name of the monosodium salt is specified.
- Patent Document 7 describes (2S) -5- (benzyloxyimino) piperidine-2-2 as a production method not via a (2S, 5S) -5-hydroxypiperidine-2-carboxylic acid derivative.
- a process for the preparation of carboxylic acid benzyl ester and (2S, 5R / S) -5- (benzyloxyamino) piperidine-2-carboxylic acid benzyl ester is disclosed.
- Patent Document 1 and Patent Document 2 show production results of racemic diazabicyclooctane derivatives, but methods for producing optically active diazabicyclooctane derivatives, optical resolution methods, optically active instrument data, In particular, there has been no report of empirical data indicating the creation of optically active substances such as optical rotation, and no actual results obtained as a single optically active substance have been shown so far.
- TFA 2,2,2-trifluoroacetyl group
- NaBH 4 sodium borohydride
- BnO benzyloxy group
- Patent Document 5 and Patent Document 6 (2S, 5R) -6- (benzyloxy) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2- is used as an optically active substance.
- Patent Documents disclosing the method of producing a racemate as the production method 1 and Patent Document 2 only.
- Patent Document 3 and Patent Document 4 disclose only a method for producing an optically active diazabicyclooctane derivative, but since this is a specific method for producing only a compound having a specific amide side chain at the 2-position, It does not suggest application value as a body.
- the introduction reaction of benzyloxyamino group via the para-trifluoromethylbenzenesulfonyloxy group disclosed in Patent Document 3 and Patent Document 4 and the intramolecular urea formation reaction using triphosgene are linked to the ester side chain at the 2-position.
- Boc is a tert-butoxycarbonyl group
- pCF 3 PhSO 2 Cl is para-trifluoromethylbenzenesulfonyl chloride
- KN (Boc) OBn is potassium N-tert-butoxycarbonyl-benzyloxyamide
- BnO is benzyl. Since the compounds of the formulas (f) and (g) shown in the above reaction formula cannot be separated directly, their structures are deprotected from the Boc group and converted into intramolecular ureas using diphosgene. , Determined by NMR after isolation.)
- Patent Document 4 discloses a method for producing (2S, 5S) -di-tert-butyl 5-hydroxypiperidine-1,2-dicarboxylate, and the tert-butoxycarbonyl group on the piperidine ring It is difficult to discriminate and deprotect tert-butyl ester, or it is not easy to distinguish tert-butyl ester from hydroxy group only after deprotection, and it is obtained by the disclosed method.
- the compound was a compound that is difficult to use directly industrially as a starting material of the common intermediate aimed by the inventors of the present application.
- the present inventors have provided an optically active diazabicyclooctane derivative, particularly 2-carboxylic acid and ester derivatives useful as a pharmaceutical intermediate of a ⁇ -lactamase inhibitor, and an easily practicable production method thereof.
- (2S, 5S) -5-hydroxypiperidine-2-carboxylic acid derivative which is a known compound, is used as a starting material, so that it is relatively short process and good reproducibility without deterioration of optical purity.
- optically active diazabicyclooctane derivative can be industrially supplied in a high yield, and the optically active diazabicyclooctane derivative obtained by such a method can be used as a pharmaceutical intermediate of a ⁇ -lactamase inhibitor As a result, the present invention has been completed.
- the present invention relates to an optically active (2S, 5R) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylic acid derivative represented by the following formula (F).
- R 1 represents CO 2 R, CO 2 M, or CONH 2
- R represents a methyl group, a tert-butyl group, an allyl group, a benzyl group, or a 2,5-dioxopyrrolidin-1-yl group
- M represents a hydrogen atom, an inorganic cation, or an organic cation
- R 2 represents a benzyl group or an allyl group.
- the present invention is also a method for producing a compound represented by the above formula (F), wherein the compound represented by the following formula (E) is converted into an intramolecular urea and then represented by the following formula (F1).
- the present invention relates to a method comprising subjecting the compound to be subjected to at least one or more of the following steps.
- This invention is also a manufacturing method of the compound represented by the said Formula (E), Comprising:
- the compound represented by the following formula (B) is trifluoroacetylated, It represents with the following formula (C) obtained.
- the present invention relates to a method comprising reacting a compound with benzyloxyamine in the presence of a hydroxyl group activator, and detrifluoroacetylating the resulting compound represented by the following formula (D).
- the present invention is an intermediate compound for producing a compound represented by the above formula (F), which is represented by the following formula (B), formula (C), formula (D), and formula (E). It also relates to the compounds represented.
- tBu represents a tert-butyl group.
- tBu represents a tert-butyl group
- TFA represents a trifluoroacetyl group.
- Bn represents a benzyl group
- tBu represents a tert-butyl group
- TFA represents a trifluoroacetyl group.
- Bn represents a benzyl group and tBu represents a tert-butyl group.
- the process for producing an optically active diazabicyclooctane derivative provided by the present invention is an optically active (2S, 5R) -7-oxo with a relatively short process and good reproducibility in good yield without deterioration of optical purity.
- -1,6-diazabicyclo [3.2.1] octane-2-carboxylic acid derivatives can be supplied industrially.
- the optically active (2S, 5R) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylic acid derivative of the present invention thus obtained can be easily crystallized.
- the present invention provides an optically active (2S, 5R) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylic acid derivative represented by the following formula (F): About.
- R 1 represents CO 2 R, CO 2 M, or CONH 2
- R represents a methyl group, a tert-butyl group, an allyl group, a benzyl group, or 2,5-dioxopyrrolidin-1-yl
- M represents a hydrogen atom, an inorganic cation, or an organic cation
- R 2 represents a benzyl group or an allyl group.
- the inorganic cation is sodium, potassium, lithium, or calcium, preferably sodium, potassium, or calcium.
- Organic cations are ammonium salts formed from amines such as trimethylamine, triethylamine, cyclohexylamine, dicyclohexylamine; quaternary ammonium salts such as tetramethylammonium, tetraethylammonium, tetrabutylammonium, triethylbenzylammonium; Preferably, it is a cyclohexyl ammonium salt.
- Preferred examples of the compound represented by formula (F) include the following compounds. (2S, 5R) -tert-butyl 6- (benzyloxy) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylate, (2S, 5R) -6- (benzyloxy) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylic acid cyclohexylamine salt, (2S, 5R) -6- (benzyloxy) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylic acid, (2S, 5R) -6- (benzyloxy) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylic acid, (2S, 5R) -6- (benzyloxy) -7-oxo-1,6-di
- the optically active (2S, 5R) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylic acid derivative represented by the general formula (F) newly provided by the present invention is:
- the compound of the formula (E) can be produced from the compound of the formula (E), but the compound of the formula (E) is obtained by a method basically represented by the following chemical reaction formula, starting from the compound of the formula (A) which is a known compound. be able to.
- Cbz is benzyloxycarbonyl group
- t-Bu is tert-butyl group
- TFA is 2,2,2-trifluoroacetyl group
- OBn is benzyloxy group
- R 2 is benzyl group, allyl group. And preferably represents a benzyl group, and the numbers in parentheses represent the number of each step
- the compound represented by the formula (F) of the present invention is a first step of removing the benzyloxycarbonyl group of the compound represented by the formula (A) to lead to the compound represented by the formula (B), piperidine nitrogen.
- the selection of the tert-butyl ester of the compound represented by the formula (A) that can be used as a starting material in the present invention is very effective in the selective removal of the trifluoroacetyl group of the compound represented by the formula (D).
- the compound of the formula (A) is a precursor of the compound represented by the formula (B). As the optimal starting material.
- this production method can be said to be a very useful production method that can selectively produce a trans-oxyamino compound without producing an unnecessary cis-benzyloxyamino compound. That is, the production method starting from the compound represented by the above formula (A) is an optically active (2S, 5R) -tert-butyl 5- (benzyloxyamino) piperidine-2-carboxylate represented by the formula (E). It is a highly useful production method as an efficient production method for rates.
- the compound represented by the formula (A) as a starting material in this production method can be produced by the method reported in Non-Patent Document 1, but a more efficient method is described in Non-Patent Document 4. It can also be produced by a method shown in the following reaction formula from a known compound represented by the following formula (k).
- the optically active (2S, 5R) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylic acid derivative represented by the formula (F) provided by the present invention has the formula (E ) Intramolecular urea conversion of the compound represented by formula (F1), and then cleaving the ester (step a), converting the compound represented by formula (F1) into a salt form of an inorganic cation or an organic cation (Step b), Step of treating acid to make free acid (Step c), Step of carbamoylating carboxylic acid (Step d), Step of esterifying carboxylic acid (Step e), Benzyl group of 6-position benzyloxy group And a method for obtaining a compound represented by the formula (F) by subjecting to at least one of a step of removing (step f) and a step of allyloxylating the 6-position (step g).
- an intramolecular urea formation step (5-1)
- the compound represented by the formula (F) in various embodiments can be obtained by passing one or more of the steps (5-2) to (5-8) following the step). More specifically, these steps can be performed by a method represented by the following chemical reaction formula.
- OBn is benzyloxy group
- t-Bu is tert-butyl group
- M 1 is cyclohexylammonium
- R 3 is methyl group, allyl group, benzyl group, 2,5-dioxopyrrolidin-1-yl group
- OAllyl represents an allyloxy group, and the numbers in parentheses indicate the number of each step
- Step 5-1 in which the compound represented by the formula (E) is converted into an intramolecular urea to form the compound represented by the formula (F1), the tert-butyl ester is cleaved.
- Step 5-2 for converting to cyclohexylammonium salt represented by formula (F1-1)
- Step 5-3 for converting cyclohexylammonium salt to a free acid represented by formula (F1-2), carboxylic acid Is converted to an allyl group by removing the benzyl group from Step (5-4) and (5-5), or the formula (F1) to form the formula (F2-4) or (F1-3).
- Step 5-8 leading to) Steps 5-9 and 5-10 cleaving the tert-butyl ester to formulas (F2-1) and (F2-2), derivatizing the carboxylic acid to formula (F2) Step 3-5 leading to step -3).
- t-Bu represents a tert-butyl group
- OBn represents a benzyloxy group
- Me represents a methyl group
- octane-2-carboxylate represented by the formula (F1) has an interplanar spacing ( d) 11.56, 10.96, 6.55, 6.00, 5.79, 5.56, 5.47, 5.25, 4.90, 4.35, 4.23, and 3.86 ⁇
- d interplanar spacing
- (2S, 5R) -methyl 6- (benzyloxy) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylate represented by the formula (F1-3a) is a powder Surface spacing (d) in the X-ray diffraction pattern 10.39, 5.86, 5.69, 5.34, 4.81, 4.44, 3.98, 3.78, 3.11, 3.03 It exists as a crystal having a characteristic peak at 2.93 and 2.77 mm, and it is particularly preferable that it is isolated and purified by a crystal having high purity of the compound and easy to handle, especially on an industrial scale. It is.
- (2S, 5R) -allyl 6- (benzyloxy) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylate represented by the formula (F1-3b) is a powder In the X-ray diffraction pattern, it exists as a crystal having a peak characteristic in the interplanar spacing (14.72, 4.91, 4.46, 4.24, and 3.67 mm, particularly on an industrial scale, It is particularly preferable that the compound is isolated and purified with crystals that have high purity and are easy to handle.
- a cyclohexylammonium salt of (2S, 5R) -6- (benzyloxy) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylic acid represented by the formula (F1-1a) Is the interplanar spacing (d) 9.95, 8.45, 6.26, 5.87, 5.52, 5.22, 5.10, 4.96, 4.73 in the powder X-ray diffraction pattern. It exists as crystals with peaks characteristic of 4.54, 4.16, 3.93, and 3.55 mm, and is isolated and purified with crystals that are highly pure and easy to handle, especially on an industrial scale. It is particularly preferred that
- (2S, 5R) -6- (benzyloxy) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylic acid represented by the formula (F1-2) is powder X
- the spacing (d) is 8.19, 7.14, 6.64, 6.29, 5.60, 5.21, 4.91, 4.60, 4.21, 3.69, It is particularly preferable that it exists as a crystal having a characteristic peak at 3.45 and 3.13 mm, and is isolated and purified by a crystal having high purity of the compound and easy to handle, particularly on an industrial scale. is there.
- (2S, 5R) -6- (benzyloxy) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxamide represented by the formula (F1-4) is a powder X-ray
- the diffraction pattern has characteristic peaks at interplanar spacing (d) of 13.06, 6.52, 5.14, 4.74, 4.63, 4.34, 3.85, and 3.72 mm. It is particularly preferable to isolate and purify crystals that exist as crystals and are easy to handle, especially on an industrial scale, with high compound purity.
- any hydrogenation catalyst can be used, and platinum oxide, palladium oxide, palladium black, palladium-carbon and the like can be preferably used.
- the catalyst can be used in a range of 0.05 to 1 w / w by weight with respect to the compound of formula (A).
- the hydrogen pressure can be from atmospheric pressure to 0.5 MPa.
- the solvent used in the reaction can be selected from water, methanol, ethanol, propanol, isopropanol, butanol, ether, diisopropyl ether, ethyl acetate, butyl acetate, toluene, tetrahydrofuran, 1,4-dioxane, alone or in combination. Can be used.
- a catalyst selected from platinum oxide, palladium oxide, palladium black, or palladium-carbon in a weight ratio of 0.05 to 0.5 w / w in methanol or ethanol can be used.
- palladium-carbon having a weight ratio of 0.05 to 0.25 w / w in ethanol can be used as a catalyst.
- the compound represented by the formula (B) produced by the first step employs usual processing means commonly used in organic chemistry such as catalyst filtration, solvent concentration, solvent exchange, salt formation, and crystallization after completion of the reaction.
- processing means commonly used in organic chemistry such as catalyst filtration, solvent concentration, solvent exchange, salt formation, and crystallization after completion of the reaction.
- it can be isolated in the form of the free base or used in the next step without purification after workup.
- TFA 2,2,2-trifluoroacetyl group and t-Bu represents tert-butyl group
- the trifluroacetylation of the compound represented by the formula (B) is performed by dissolving the compound of the formula (B) in an appropriate solvent and adding an excess of the trifluoroacetylating agent in the presence of an excess base. This is carried out by cleaving only the 5-position trifluoroacetyl group after reacting to give a 1,5-ditrifluoroacetyl form.
- the base used in the reaction is an inorganic base such as sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, triethylamine, diisopropylethylamine, tributylamine, 1,8-diazabicyclo [5.4. 0] can be selected from organic bases such as undec-7-ene, pyridine, 2-picoline, 2,6-lutidine and used in the range of 2 to 6 molar equivalents relative to the compound of formula (B).
- organic bases such as undec-7-ene, pyridine, 2-picoline, 2,6-lutidine
- Trifluoroacetylating agents are trifluoroacetic acid, ethyl trifluoroacetate, trifluoroacetic anhydride, trifluoroacetyl chloride, trifluoroacetylsuccinimide ester, trifluoroacetylbenzotriazole ester, trifluoroacetylpentafluorophenyl It can be selected from esters, 2-trifluoroacetoxypyridine, dodecyltrifluorothioacetate and can be used in the range of 1.5 to 3 molar equivalents relative to the compound of formula (B).
- the trifluoroacetylation reaction is carried out in the temperature range of ⁇ 30 to + 50 ° C.
- Cleavage of the 5-position trifluoroacetoxy group is carried out after post-treatment of trifluoroacetylation or continuously by stirring in the presence of the above base in water or an alcohol solvent such as methanol or ethanol from room temperature to warming. it can.
- Solvents used in the reaction are water, methanol, ethanol, propanol, isopropanol, butanol, dichloromethane, 1,2-dichloroethane, chloroform, ether, diisopropyl ether, ethyl acetate, butyl acetate, tetrahydrofuran, 1,4-dioxane, N, N It can be selected from -dimethylformamide and N, N-dimethylacetamide, and can be used alone or in combination.
- tertiary amine selected from 4 to 5 molar equivalents of triethylamine, diisopropylethylamine, or tributylamine in dehydrated dichloromethane or tetrahydrofuran.
- trifluoroacetic anhydride is added dropwise and treated with water at room temperature.
- the compound represented by the formula (C) produced by the second step can be easily obtained by adopting usual processing means commonly used in organic chemistry such as extraction, washing, drying, solvent concentration, and solvent exchange after completion of the reaction. It can be used in the next step without being isolated or purified after workup.
- TFA represents a 2,2,2-trifluoroacetyl group
- t-Bu represents a tert-butyl group
- OBn represents a benzyloxy group
- the compound of the formula (C) is dissolved in a suitable solvent, cooled, and a hydroxyl group activator is added dropwise by means such as dropping in the presence of a base, and then benzyloxyamine and a base are successively added.
- a hydroxyl group activator is added dropwise by means such as dropping in the presence of a base, and then benzyloxyamine and a base are successively added.
- it can be carried out by reacting.
- Bases present in the reaction solution are organic bases such as triethylamine, diisopropylethylamine, tributylamine, 1,8-diazabicyclo [5.4.0] undec-7-ene, pyridine, 2-picoline, and 2,6-lutidine. And is used in the range of 2 to 3 molar equivalents relative to the compound of formula (C).
- the hydroxyl group activator can be selected from trifluoromethanesulfonyl chloride and trifluoromethanesulfonic anhydride, and is used in the range of 1 to 1.5 molar equivalents relative to the compound represented by the formula (C).
- the reaction is carried out at a temperature ranging from ⁇ 50 ° C. to + 30 ° C.
- Benzyloxyamine is used in a range of 2 to 3 molar equivalents relative to the compound represented by the formula (C).
- the solvent used in the reaction may be selected from dichloromethane, 1,2-dichloroethane, toluene, ethyl acetate, butyl acetate, tetrahydrofuran, 1,4-dioxane, acetonitrile, N, N-dimethylformamide, N, N-dimethylacetamide. it can.
- an aromatic amine selected from 1.0 to 1.5 molar equivalents of pyridine, 2-picoline, or 2,6-lutidine in dehydrated acetonitrile or tetrahydrofuran.
- 1.0 to 1.2 molar equivalents of trifluoromethanesulfonic anhydride was added dropwise and stirred at the same temperature until the compound of formula (C) disappeared, then 2 to 3 molar equivalents of benzyloxyamine And 1.0 to 1.5 molar equivalents of 2,6-lutidine are added, and the reaction is carried out at ⁇ 5 to + 15 ° C. for 2 to 3 days.
- the compound represented by the formula (D) produced by the third step can be easily obtained by adopting usual processing means commonly used in organic chemistry such as extraction, washing, drying, solvent concentration, and solvent exchange after completion of the reaction. It can be used in the next step without being isolated or purified after workup.
- the removal of the trifluoroacetyl group of the compound represented by the formula (D) can be carried out by dissolving the compound of the formula (D) in an appropriate solvent and solvolysis in the presence of an inorganic base. it can.
- the inorganic base can be selected from inorganic bases such as sodium hydroxide, potassium hydroxide, lithium hydroxide, cesium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, and the like, with respect to the compound represented by the formula (D) Used in the range of 1 to 3 molar equivalents.
- inorganic bases such as sodium hydroxide, potassium hydroxide, lithium hydroxide, cesium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, and the like, with respect to the compound represented by the formula (D) Used in the range of 1 to 3 molar equivalents.
- the solvent used in the reaction can be selected from water, methanol, ethanol, tetrahydrofuran and 1,4-dioxane, and can be used alone or in combination.
- the reaction temperature is preferably 30 ° C. or lower.
- hydrolysis is carried out in an aqueous dioxane or tetrahydrofuran at 0 ° C. to room temperature with an inorganic base selected from 1.5 to 2.5 molar equivalents of sodium hydroxide, potassium hydroxide, lithium hydroxide, or cesium hydroxide. .
- hydrolysis with 2 molar equivalents of sodium hydroxide is performed at a temperature of 0 ° C. to 30 ° C. in hydrous dioxane.
- the compound represented by the formula (E) produced by the fourth step is neutralized, extracted, washed, dried, solvent concentrated, solvent exchanged, salt formed, crystallized, etc.
- a general processing means which is widely used it can be easily isolated as a free base, for example, or used in the next step without purification after post-treatment.
- t-Bu represents a tert-butyl group and OBn represents a benzyloxy group
- the base used in the reaction is triethylamine, diisopropylethylamine, tributylamine, 1,8-diazabicyclo [5.4.0] undec-7-ene, pyridine, 2-picoline, 2,6-lutidine, 4-dimethylaminopyridine.
- the phosgene equivalent can be selected from phosgene, diphosgene, triphosgene, preferably phosgene and diphosgene, and is used in the range of 0.5 to 2 molar equivalents relative to the compound represented by the formula (E).
- the solvent used for the reaction is selected from dichloromethane, 1,2-dichloroethane, toluene, ethyl acetate, butyl acetate, tetrahydrofuran, 1,4-dioxane, acetonitrile, N, N-dimethylformamide, N, N-dimethylacetamide and the like. be able to.
- the reaction concentration is in the range of 0.01 to 0.1M.
- the reaction temperature is ⁇ 20 to + 30 ° C.
- a tertiary amine selected from 2 to 3 molar equivalents of triethylamine, diisopropylethylamine, or tributylamine in dehydrated acetonitrile or tetrahydrofuran at a concentration of 0.01 to 0.1 M at ⁇ 5 to 30 ° C., or Add 0.05 to 1.5 molar equivalents of 4-dimethylaminopyridine, 0.5 to 1.0 molar equivalents of diphosgene or 1.0 to 2.0 molar equivalents of phosgene, and stir at room temperature.
- the compound represented by the formula (F1) produced by the step 5-1 is an organic compound such as neutralizing excess base after completion of the reaction, solvent concentration, extraction, washing, drying, solvent concentration, solvent exchange, and crystallization. It can be easily isolated by adopting a usual chemical treatment means.
- OBn represents a benzyloxy group.
- Cleavage of the tert-butyl ester with an acid or metal salt of the compound represented by formula (F1) is carried out by dissolving the compound of formula (F1) in a suitable solvent and treating with an acid or metal salt.
- Acids used in the reaction are inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, formic acid, acetic acid, trifluoroacetic acid, tetrafluoroboric acid, methanesulfonic acid, para-toluenesulfonic acid, trifluoromethane
- organic acids such as sulfonic acids.
- it can be selected from trifluoroacetic acid, formic acid, methanesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, or sulfuric acid, and in the range of 1 molar equivalent to solvent amount relative to the compound represented by formula (F1). Used.
- the metal salt used in the reaction can be selected from lithium iodide, magnesium iodide, zinc bromide, cerium chloride, titanium tetrachloride, boron trifluoride, aluminum chloride, and aluminum bromide.
- formula (F1) Used in the range of 1 to 6 molar equivalents relative to the compound represented.
- the solvent used in the reaction can be selected from water, methanol, ethanol, isopropanol, ethyl acetate, butyl acetate, 1,4-dioxane, dichloromethane, 1,2-dichloroethane, and toluene, and used alone or in combination. be able to.
- the reaction is carried out in the range of ⁇ 25 to + 25 ° C.
- the mixture is stirred at 0 to + 25 ° C. in formic acid or in 2 to 3 molar equivalents of sulfuric acid in dichloromethane or trifluoroacetic acid / dichloromethane (1/1).
- the mixture is stirred at 0 to + 25 ° C. in trifluoroacetic acid / dichloromethane (1/1).
- a salt with cyclohexylamine is carried out by adding cyclohexylamine in an appropriate solvent after performing the solvent concentration, extraction, washing, drying, solvent concentration, and solvent exchange as necessary after completion of the above reaction. It can be carried out.
- the number of equivalents of cyclohexylamine to be added is selected from 1 to 4 molar equivalents relative to the compound of formula (F1). Note that this step is a salt formation step for the synthesis of the compound of formula (F1-1) in which M is cyclohexylammonium, but M is an inorganic cation other than cyclohexylammonium or an organic cation (F ),
- the base used for salt formation is an amine such as trimethylamine, triethylamine, cyclohexylamine, dicyclohexylamine; tetramethylammonium hydroxide, tetraethylammonium hydroxide, tetrabutylammonium hydroxide, hydroxylated Organic ammonium salts such as triethylbenzylammonium; can be selected from alkali or alkaline earth metal salts such as sodium, potassium, lithium, or calcium of 2-ethylhexanoic acid.
- the solvents used in salt formation are methanol, ethanol, isopropanol, acetone, methyl ethyl ketone, ethyl acetate, It can be selected from butyl acetate, diethyl ether, diisopropyl ether, tetrahydrofuran, 1,4-dioxane, dichloromethane, 1,2-dichloroethane, toluene, hexane, and can be used alone or in combination.
- cyclohexylamine Preferably, 1 to 4 molar equivalents of cyclohexylamine are added to the compound of formula (F1) in ethyl acetate to form a salt and crystallize.
- the salt represented by the formula (F1-1) produced by the step 5-2 is formed by adopting usual processing means commonly used in organic chemistry such as filtration, washing and drying after salt formation and crystallization. It can be easily isolated and stored and is particularly excellent as an industrial production intermediate.
- OBn represents a benzyloxy group.
- the liberation of the carboxylic acid by the acid of the salt of the compound represented by the formula (F1-1) is carried out by dissolving the compound of the formula (F1-1) in an aqueous solution of an appropriate acid and extracting it with an organic solvent.
- the acid used in the reaction can be selected from inorganic acids such as hydrochloric acid, sulfuric acid, potassium hydrogen sulfate, phosphoric acid, nitric acid, or sodium dihydrogen phosphate.
- the organic solvent used for extraction can be selected from organic solvents such as dichloromethane and ethyl acetate.
- the compound of the formula (F1-1) is dissolved in an inorganic acid aqueous solution selected from hydrochloric acid, sulfuric acid, potassium hydrogen sulfate, or sodium dihydrogen phosphate, and extracted with an organic solvent such as ethyl acetate.
- an inorganic acid aqueous solution selected from hydrochloric acid, sulfuric acid, potassium hydrogen sulfate, or sodium dihydrogen phosphate, and extracted with an organic solvent such as ethyl acetate.
- the compound of the formula (F1-1) is dissolved in a saturated aqueous solution of sodium dihydrogen phosphate or dilute hydrochloric acid and extracted into an organic solvent such as ethyl acetate.
- the carboxylic acid represented by the formula (F1-2) produced by the step 5-3 is obtained by adopting usual processing means commonly used in organic chemistry such as solvent extraction, concentration, solvent exchange, and crystallization. It can be used in the next step without isolation or isolation.
- the compound represented by the formula (F1-2) is reacted with a carboxylic acid activator and concentrated aqueous ammonia in a suitable solvent in the presence of a base, or the active ester is isolated and concentrated.
- Carboxamide is obtained by reacting with aqueous ammonia.
- Bases used in the reaction are inorganic bases such as sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, triethylamine, diisopropylethylamine, tributylamine, 1,8-diazabicyclo [5.4. .0] can be selected from organic bases such as undec-7-ene, pyridine, 2-picoline, 2,6-lutidine, 4-dimethylaminopyridine, preferably selected from triethylamine, diisopropylethylamine, tributylamine And can be used in the range of 0.8 to 1.5 molar equivalents relative to the compound represented by Formula (F1-2).
- organic bases such as undec-7-ene, pyridine, 2-picoline, 2,6-lutidine, 4-dimethylaminopyridine, preferably selected from triethylamine, diisopropylethylamine, tributylamine
- Carboxylic acid activators used in the reaction include acid chlorides such as ethyl chloroformate, isobutyl chloroformate, pivaloyl chloride and 2,4,6-trichlorobenzoyl chloride, acid anhydrides such as isovaleric acid anhydride and pivalic acid anhydride.
- Acid chlorides such as ethyl chloroformate, isobutyl chloroformate, and pivaloyl chloride
- Products preferably ethyl chloroformate, isobutyl chloroformate, and pivaloyl chloride, and used in the range of 0.8 to 1.5 molar equivalents relative to the compound represented by formula (F1-2).
- Solvents used in the reaction are water, dichloromethane, 1,2-dichloroethane, toluene, ethyl acetate, butyl acetate, tetrahydrofuran, 1,4-dioxane, acetonitrile, N, N-dimethylformamide, N, N-dimethylacetamide, pyridine And can be used alone or in combination.
- This step can be performed in the presence of a condensing agent.
- condensing agents include carbodiimides such as N, N′-dicyclohexylcarbodiimide, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride; or 1-hydroxybenzotriazole, N-hydroxy Benzotriazol-1-yloxy-tris (dimethylamino) phosphonium hexafluorophosphate, 2-chloro-1-methylpyridinium iodide combined with a catalyst such as succinimide, 2-hydroxypyridine-N-oxide, ( 4,6-dimethoxy-1,3,5-triazin-2-yl) -4-methylmorpholinium chloride; and the like.
- the condensing agent is used in the range of 0.8 to 1.5 molar equivalents relative to the compound represented by the formula (F1-2).
- Concentrated aqueous ammonia is used in the range of 5 to 100 molar equivalents relative to the compound represented by the formula (F1-2).
- reaction temperature is ⁇ 20 to + 25 ° C.
- this step comprises 1.1 molar equivalents of ethyl chloroformate in the presence of a tertiary amine selected from 1.2 molar equivalents of triethylamine, diisopropylethylamine, or tributylamine in dehydrated dichloromethane at ⁇ 5 to + 5 ° C.
- a mixed acid anhydride reagent selected from isobutyl chloroformate or pivalic acid chloride, it is reacted with 5 to 50 molar equivalents of concentrated aqueous ammonia.
- 1.1 molar equivalents of isobutyl chloroformate are reacted in dichloromethane in the presence of 1.2 molar equivalents of triethylamine at ⁇ 5 to + 5 ° C. followed by 5 to 20 molar equivalents of concentrated aqueous ammonia. .
- the carboxamide compound represented by the formula (F1-4) produced by the step 5-4 is subjected to usual processing means commonly used in organic chemistry such as solvent extraction, washing, drying, solvent concentration, solvent exchange, and crystallization. By adopting, it can be isolated.
- OBn represents a benzyloxy group
- esterification of the compound represented by formula (F1-2) and the compound represented by formula (F2-2) is carried out in the presence of an alkylating agent and a base in a suitable solvent.
- an alkylating agent Alkyl halide, allyl halide, or benzyl halide; or by reacting a carboxylic acid activator or dehydrating condensing agent with an alcohol in the presence of a base.
- Alkylating agents used in the reaction are diazoalkyl such as diazomethane, trimethylsilyldiazomethane, diphenyldiazomethane, methyl iodide, ethyl iodide, allyl chloride, allyl bromide, benzyl chloride, benzyl bromide, para-nitrobenzyl bromide, It can be selected from halogen compounds such as para-methoxybenzyl bromide.
- diazoalkyl such as diazomethane, trimethylsilyldiazomethane, diphenyldiazomethane, methyl iodide, ethyl iodide, allyl chloride, allyl bromide, benzyl chloride, benzyl bromide, para-nitrobenzyl bromide, It can be selected from halogen compounds such as para-methoxybenzyl bromide.
- the base used in the reaction is an inorganic base such as sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, triethylamine, diisopropylethylamine, tributylamine, 1,8-diazabicyclo [ 5.4.0] can be selected from organic bases such as undec-7-ene, pyridine, 2-picoline, 2,6-lutidine, 4-dimethylaminopyridine.
- the carboxylic acid activator or condensing agent used in the reaction is carbodiimide alone such as N, N′-dicyclohexylcarbodiimide, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride; or 1-hydroxybenzotriazo Benzotriazol-1-yloxy-tris (dimethylamino) phosphonium hexafluorophosphate, 2-chloro-1-methylpyridinium iodide combined with a catalyst such as benzene or 2-hydroxypyridine-N-oxide, (4 , 6-Dimethoxy-1,3,5-triazin-2-yl) -4-methylmorpholinium carboxylic acid activator such as chloride; ethyl chloroformate, isobutyl chloroformate, pivaloyl chloride, 2,4,6 chloride -Acid chlorides such as trichlorobenzoyl It can be selected from; isovaleric acid
- Solvents used for the esterification reaction are water, dichloromethane, 1,2-dichloroethane, toluene, ethyl acetate, butyl acetate, tetrahydrofuran, 1,4-dioxane, acetonitrile, N, N-dimethylformamide, N, N-dimethylacetamide , Pyridine can be selected and used alone or in combination.
- the alcohol used in the reaction can be selected from methanol, allyl alcohol, benzyl alcohol, and 2,5-dioxopyrrolidin-1-ol.
- allyl esterification When allyl esterification is performed, it is preferable to react with 1 to 3 molar equivalents of allyl bromide in N, N-dimethylformamide in the presence of 1 to 3 molar equivalents of sodium bicarbonate at room temperature.
- reaction is carried out in dichloromethane with isobutyl chloroformate in the presence of a tertiary amine followed by N-hydroxysuccinimide. It is preferable to do so.
- the compound represented by the formula (F2-3c), which is a specific compound of the compound employs usual processing methods commonly used in organic chemistry such as solvent extraction, liquid separation washing, drying, solvent concentration, and crystallization after completion of the reaction. Can be isolated.
- the cleavage of the methyl ester of the compound represented by the formula (F1-3a) obtained by the above method is performed by dissolving the compound of the formula (F1-3a) in an appropriate solvent and using an appropriate base. Can be carried out by solvolysis in the presence of.
- the inorganic base used in the reaction can be selected from inorganic bases such as sodium carbonate, potassium carbonate, cesium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, cesium hydroxide, and the like (F1-3a) Used in the range of 1.0 to 1.5 molar equivalents relative to the compound represented.
- inorganic bases such as sodium carbonate, potassium carbonate, cesium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, cesium hydroxide, and the like (F1-3a) Used in the range of 1.0 to 1.5 molar equivalents relative to the compound represented.
- the solvent used in the reaction can be selected from water, methanol, ethanol, propanol, isopropanol, butanol, ether, diisopropyl ether, toluene, tetrahydrofuran, and 1,4-dioxane, and can be used alone or in combination.
- the reaction temperature is ⁇ 20 to + 25 ° C.
- the compound of formula (F1-3a) is stirred with 1.0 to 1.2 equivalents of lithium hydroxide at ⁇ 10 to + 10 ° C. in water-tetrahydrofuran.
- the compound of formula (F1-3a) is stirred with 1.0 to 1.1 equivalents of lithium hydroxide in water-tetrahydrofuran at ⁇ 5 to + 5 ° C.
- the carboxylic acid represented by (F1-2) produced by Step 5-6.1 is subjected to organic chemistry such as solvent concentration, acidification, solvent extraction, liquid separation washing, drying, solvent concentration, salt formation after the reaction is completed. It can be used in the next step either by isolation or without isolation by employing the above general processing means.
- the cleavage of the allyl ester of the compound represented by the formula (F1-3b) is performed by dissolving the compound of the formula (F1-3b) in an appropriate solvent and in the presence of a catalyst with an appropriate nucleophile. It can be implemented by processing.
- the catalyst used in the reaction can be selected from palladium acetate, tetrakis (triphenylphosphine) palladium, dichloro-bis (triphenylphosphine) palladium, chloro-tris (triphenylphosphine) rhodium, and lithium dimethylcopper. It can be used in the range of 0.01 to 0.1 molar equivalents relative to the compound represented by F1-3b).
- the nucleophile used in the reaction can be selected from sodium 2-ethylhexanoate, sodium 2-methylhexanoate, pyrrolidine, dimedone, benzyloxyamine, sodium benzenesulfenate and represented by the formula (F1-3b) It can be used in the range of 1 to 2 molar equivalents relative to the represented compound.
- the solvent used in the reaction can be selected from water, methanol, ethanol, propanol, isopropanol, butanol, ether, diisopropyl ether, ethyl acetate, butyl acetate, dichloromethane, dichloroethane, toluene, tetrahydrofuran, 1,4-dioxane, and acetonitrile. These can be used alone or in combination.
- the reaction temperature is selected from ⁇ 20 to + 25 ° C.
- the compound represented by the formula (F1-3b) is converted into 0.01 to 0.05 molar equivalents of palladium acetate, dichloro-bis (triphenylphosphine) in tetrahydrofuran, acetonitrile or dichloromethane at room temperature.
- palladium or tetrakis (triphenylphosphine) palladium stir with 1 to 2 molar equivalents of sodium 2-ethylhexanoate, pyrrolidine or dimedone.
- the compound represented by formula (F1-3b) is added in an amount of 1 to 1.5 mol in dichloromethane in the presence of 0.01 to 0.03 molar equivalent of tetrakis (triphenylphosphine) palladium at 20 ° C. Stir with an equivalent amount of sodium 2-ethylhexanoate.
- the compound obtained by cleaving the allyl ester thus obtained is treated with cyclohexylamine to obtain a compound of the formula (F1-1a), and then an inorganic acid selected from hydrochloric acid, sulfuric acid, potassium hydrogen sulfate, or sodium dihydrogen phosphate
- an inorganic acid selected from hydrochloric acid, sulfuric acid, potassium hydrogen sulfate, or sodium dihydrogen phosphate
- the compound of formula (F1-2) can be obtained by releasing the carboxylic acid by treatment with
- the carboxylic acid represented by the formula (F1-2) produced by this Step 5-6.2 is organically concentrated after the reaction, such as solvent concentration, acidification, solvent extraction, liquid separation washing, drying, solvent concentration, and salt formation. It can be used in the next step either by isolation or without isolation by adopting a usual chemical treatment means.
- Concentrated aqueous ammonia is used in the range of 5 to 100 molar equivalents relative to the compound represented by the formula (F1-3d).
- the solvent used in the reaction is selected from water, dichloromethane, 1,2-dichloroethane, toluene, ethyl acetate, butyl acetate, tetrahydrofuran, 1,4-dioxane, acetonitrile, N, N-dimethylformamide, N, N-dimethylacetamide Can be used alone or in combination.
- reaction temperature is ⁇ 20 to + 25 ° C.
- the compound represented by the formula (F1-3d) is preferably reacted with 5 to 50 molar equivalents of concentrated aqueous ammonia at ⁇ 5 to + 5 ° C. in dehydrated dichloromethane.
- the compound represented by the formula (F1-3d) is reacted with concentrated ammonia water at 5 to 20 molar equivalent in dichloromethane at ⁇ 5 to + 5 ° C.
- the carboxamide compound represented by the formula (F1-4) produced by the step 5-7 is subjected to usual processing means commonly used in organic chemistry such as solvent extraction, washing, drying, solvent concentration, solvent exchange, and crystallization. By adopting, it can be isolated.
- the compound of the formula (F1) is dissolved in an appropriate solvent, followed by a hydrogenation reaction using a catalyst, followed by a base. It can be carried out by carrying out the allylation reaction in the presence.
- the catalyst used in the reaction can be selected from any hydrogenation catalyst, and preferably Raney-nickel, platinum oxide, palladium oxide, palladium black, palladium-carbon, or the like can be used.
- the hydrogen pressure can be from atmospheric pressure to 0.5 MPa.
- the solvent used in the hydrogenation reaction can be selected from water, methanol, ethanol, propanol, isopropanol, butanol, ether, diisopropyl ether, ethyl acetate, butyl acetate, toluene, tetrahydrofuran, 1,4-dioxane, alone or in combination. Can be used.
- the hydrogenation step is preferably performed in methanol or ethanol using a catalyst selected from platinum oxide, palladium oxide, palladium black, or palladium-carbon.
- palladium-carbon is used in ethanol using a catalyst.
- the 6-hydroxy form of the benzyl group cleaved obtained by the hydrogenation step is isolated by adopting usual processing methods commonly used in organic chemistry such as catalyst filtration, solvent concentration, and solvent exchange after completion of the reaction. It can be used for the next process without doing.
- Bases used for the allylation reaction are inorganic bases such as sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, triethylamine, diisopropylethylamine, tributylamine, 1,8-diazabicyclo [5.4.0]
- a compound represented by the formula (F1) which can be selected from organic bases such as undec-7-ene, pyridine, 2-picoline, 2,6-lutidine, 4-dimethylaminopyridine, etc. Can be used in the range of 1.0 to 3 molar equivalents.
- the allylating agent used in the allylation reaction can be selected from allyl chloride and allyl bromide, and can be used in the range of 1.0 to 3 molar equivalents relative to the compound represented by the formula (F1).
- the solvent used for the allylation reaction is selected from dichloromethane, 1,2-dichloroethane, toluene, ethyl acetate, butyl acetate, tetrahydrofuran, 1,4-dioxane, acetonitrile, N, N-dimethylformamide, N, N-dimethylacetamide. be able to.
- the reaction temperature is 0 to + 25 ° C.
- the allylation reaction step is preferably an inorganic base selected from 1 to 2 molar equivalents of anhydrous sodium carbonate, potassium carbonate, cesium carbonate in dehydrated acetonitrile, N, N-dimethylformamide, or N, N-dimethylacetamide. In the presence of 1 to 2 molar equivalents of allyl bromide at room temperature.
- the compound represented by the formula (F2) produced by the step 5-8 is subjected to usual processing means commonly used in organic chemistry such as solvent concentration, solvent exchange, liquid separation washing, drying, and solvent concentration after completion of the reaction. It can be isolated by adopting it.
- the cleavage of the tert-butyl ester with the acid of the compound represented by the formula (F2) is carried out by the same method as in Step 5-2 by dissolving the compound of the formula (F2) in an appropriate solvent.
- the acid trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, or sulfuric acid can be preferably used.
- treatment with cyclohexylamine gives cyclohexylamine. Get salt.
- the salt represented by the formula (F2-1a) produced by the step 5-9 is obtained by adopting usual processing means commonly used in organic chemistry such as filtration, washing and drying after salt formation and crystallization. It can be easily isolated and stored, and can be said to be particularly excellent as an industrial production intermediate.
- the liberation of the carboxylic acid by the acid of the salt represented by the formula (F2-1a) is carried out by dissolving the compound of the formula (F2-1a) in an aqueous solution of an appropriate acid and using the same method as in Step 5-3.
- an inorganic acid such as hydrochloric acid, sulfuric acid, potassium hydrogen sulfate, or sodium dihydrogen phosphate can be used.
- the carboxylic acid represented by the formula (F2-2) produced by the step 5-10 is isolated by adopting usual processing means commonly used in organic chemistry such as solvent extraction, concentration and solvent exchange. Or it can use for the next process, without isolating.
- Bn represents a benzyl group
- the compounds represented by the following formulas (F1), (F1-3a), and (F1-3b) obtained by the above steps can be crystallized from, for example, ethyl acetate and a hexane solution.
- the compound represented by the formula (F1-1a) can be crystallized from, for example, ethyl acetate-ether.
- the compound represented by the formula (F1-2) can be crystallized from, for example, ethyl acetate-hexane.
- the compound represented by the formula (F1-4) can be crystallized from, for example, a chloroform and hexane solution.
- t-Bu represents a tert-butyl group
- OBn represents a benzyloxy group
- Me represents a methyl group
- the compounds represented by the formulas (F1), (F1-3a), (F1-3b), (F1-1a), (F1-2), and (F1-4) that can be produced as described above are obtained by using a polarizing microscope. It can be obtained as a crystal by observation by X-ray diffraction and powder X-ray diffraction analysis, and is identified by having a characteristic peak particularly in powder X-ray diffraction analysis. The peak patterns are shown in Tables 1 to 6 below.
- the compound represented by the formula (F) of the present invention can be used as a production intermediate for obtaining a compound represented by the following formula (H). Therefore, starting from the compound represented by the formula (F) of the present invention, a compound represented by the following formula (H) and an enantiomer thereof were produced, and biological activities were compared.
- a compound represented by the formula (H) was produced from a compound represented by the formula (F1-4) among the compounds represented by the formula (F) obtained by the production method of the present application.
- the compound represented by the formula (H) showed activity. It was shown that the compound represented by s) shows no activity. Therefore, it was confirmed that the compound of the formula (F) obtainable by the method of the present invention is an enantiomer particularly useful as an active pharmaceutical ingredient and its intermediate.
- TAZ is Tazobactam
- IC 50 is the enzyme inhibitory activity against AmpC
- MIC is the antibacterial activity of piperacillin (PIPC, Piperacillin) when the compound is used at 4 ⁇ g / mL)
- the compounds represented by the formulas (F1-2) and (F1-4) can be used to produce an optically active form of a ⁇ -lactamase inhibitor having a diazabicyclooctane skeleton exemplified in Patent Documents 1 to 6, or It can also be used as an important intermediate for searching for new ⁇ -lactamase inhibitors with high efficacy, as well as for drug development.
- the biological activity of the compounds represented by the above formulas (H) and (s) can be measured as follows. That is, enzyme inhibitory activity (IC 50 value) using nitricefin as a substrate for AmpC enzyme which is class-C type ⁇ -lactamase was determined, and the presence or absence of inhibitory activity was compared with the intensity.
- antibacterial activity of PIPC is measured by measuring the combined antibacterial activity (MIC) when piperacillin (PIPC, Piperacillin) is used in combination with formula (H) or (s) as an antibacterial agent using constitutive AmpC producing Pseudomonas aeruginosa We evaluated whether we were able to revive power.
- an infectious disease therapeutic agent comprising a ⁇ -lactamase inhibitor containing (2S, 5R) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylic acid derivative
- a ⁇ -lactamase inhibitor containing (2S, 5R) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylic acid derivative There is also provided the use of the following specific compounds of formula (F) for the production of (2S, 5R) -tert-butyl 6- (benzyloxy) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylate; (2S, 5R) -methyl 6- (benzyloxy) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylate; (2S, 5R) -allyl 6- (benzyloxy)
- Step 2 (S) -tert-butyl 2- (benzyloxycarbonylamino) -5-oxo-6-dimethylsulfoxonium hexanoate
- N-dimethylformamide 585 mL was added 36.8 g (279 mmol) of potassium tert-butoxide under an argon atmosphere, and the mixture was stirred at room temperature for 1 hour.
- 87.0 g (272 mmol) of (S) -1-benzyl 2-tert-butyl 5-oxopyrrolidine-1,2-dicarboxylate (272 mmol) is added over 20 minutes at 5 ° C. or less (dehydrated N, N-dimethylformamide ( 87 mL), and allowed to react at the same temperature for 1 hour.
- the reaction mixture was added to ice-cold water (2.6 L), saturated with sodium chloride, extracted with ethyl acetate (2.6 L ⁇ 1 time, 1.3 L ⁇ 2 times, 650 mL ⁇ 4 times), and the solvent of the organic layer was distilled off under reduced pressure. .
- Step 3 (S) -1-benzyl 2-tert-butyl 5-oxopiperidine-1,2-dicarboxylate
- the crystals of the title compound showed a characteristic peak pattern as shown in Table 8 below in the powder X-ray diffraction pattern.
- the crystals of the title compound exhibited a characteristic peak pattern as shown in Table 9 below in the powder X-ray diffraction pattern.
- the crystals of the title compound showed a characteristic peak pattern as shown in Table 10 below in the powder X-ray diffraction pattern.
- the reaction mixture was diluted with ethyl acetate, partitioned with saturated aqueous sodium dihydrogen phosphate solution, the aqueous layer was extracted twice with ethyl acetate, and the combined organic layers were dried over anhydrous sodium sulfate.
- the residue obtained by concentrating the solvent under reduced pressure was dissolved in ethyl acetate, cyclohexylamine (33 mg) was added, and the precipitated solid was collected by filtration and washed with ether.
- the crystals of the title compound showed a characteristic peak pattern as shown in Table 11 below in the powder X-ray diffraction pattern.
- the obtained solid was recrystallized from ethyl acetate-hexane, and the resulting precipitate was collected by filtration.
- the wet crystals were washed with hexane and then dried at room temperature under reduced pressure to give the title compound as a colorless crystalline powder.
- the crystals of the title compound showed a characteristic peak pattern as shown in Table 12 below in the powder X-ray diffraction pattern.
- the title compound was obtained from the cyclohexylamine salt of (2S, 5R) -6- (allyloxy) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylic acid according to the method of Example 9. .
- the crystals of the title compound showed a characteristic peak pattern as shown in Table 13 below in the powder X-ray diffraction pattern.
- Step 1 (2R / S, 5S / R) -tert-butyl 6- (benzyloxy) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylate
- Step 3 (2R, 5S) -6- (benzyloxy) -7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylic acid cyclohexylamine salt (F1-1a)
- Step 7 (2R, 5S) -1,6-diazabicyclo [3.2.1] octane-2-carboxamide, 7-oxo-6- (sulfoxy) -monosodium salt (s)
- Example 25 The ⁇ -lactamase enzyme inhibitory activity of the compounds prepared in Examples 23 and 24 and the combined antibacterial activity of PIPC were measured.
- the structural formula of the test substance is as shown in Table 14 below.
- ⁇ -lactamase enzyme inhibitory activity The DNA encoding the region excluding the signal peptide of AmpC, which is ⁇ -lactamase, was amplified by PCR using the P. aeruginosa PAO1 genome as a template. This PCR product was incorporated into pET-28b (+) vector (Merck), introduced into E. coli BL21 (Merck), and induced at 20 ° C. under the induction of 1 mM Isopropyl- ⁇ -D-( ⁇ )-thiogalactopyranoside (Nararai Tesque). After overnight culture, AmpC was expressed. After recovering the cells, AmpC was purified from the cell extract obtained by sonication at 4 ° C. using CM Sepharose Fast Flow (GE Healthcare) and HiTrap Heparin HP (GE Healthcare).
- nitrocefin (Oxoid) with a final concentration of 100 ⁇ M was used as a substrate, 2.5% DMSO, 10 ⁇ g / mL bovine serum-derived albumin (Sigma-Aldrich), pH 7.0, 50 mM phosphate buffer. was used as a reaction solution.
- a test substance compound shown in Table 14
- AmpC final concentration 0.5 nM
- Nitrocefin was added to each well, mixed, reacted at 30 ° C.
- an agar plate containing a test substance having a final concentration of 4 ⁇ g / mL and each concentration of PIPC was prepared in Mueller-Hinton agar (Becton, Dickinson and Company), and cation-adjusted Muller-Hinton broth (Becton, Dickinson and Company). ) was prepared in the same medium so that the overnight cultured bacteria 10 4 CFU / spot with were inoculated into the drug-containing plates. This drug-containing plate was cultured overnight at 35 ° C., and the minimum drug concentration at which no bacterial growth was observed was defined as MIC. The results were as shown in Table 16.
Abstract
Description
R1は、CO2R、CO2M、またはCONH2を表し、
Rは、メチル基、tert-ブチル基、アリル基、ベンジル基、または2,5-ジオキソピロリジン-1-イル基を表し、
Mは、水素原子、無機カチオン、または有機カチオンを表し、
R2は、ベンジル基またはアリル基を表す。)
工程a エステルを切断する工程
工程b 無機カチオン、または有機カチオンの塩形態にする工程
工程c 酸処理し遊離酸にする工程
工程d カルボン酸をカルバモイル化する工程
工程e カルボン酸をエステル化する工程
工程f 6位ベンジルオキシ基のベンジル基を除去する工程
工程g 6位をアリルオキシ化する工程
更にまた、本発明は、上記式(F)で表される化合物を製造するための中間体化合物である、下記式(B)、式(C)、式(D)、および式(E)で表される化合物にも関する。
(2S,5R)-tert-ブチル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート、
(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸シクロヘキシルアミン塩、
(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸、
(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキサミド、
(2S,5R)-メチル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート、
(2S,5R)-アリル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート、
(2S,5R)-ベンジル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート、
(2S,5R)-2,5-ジオキソピロリジン-1-イル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート、
(2S,5R)-tert-ブチル 6-(アリルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート、
(2S,5R)-6-(アリルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸シクロヘキシルアミン塩、
(2S,5R)-6-(アリルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸、
(2S,5R)-ベンジル 6-(アリルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート。
式(E)で表される化合物から式(F)で表される化合物を得るための上記の方法のより具体的態様としては、下記に示すように、分子内ウレア化の工程(5-1)工程に続き、(5-2)工程から(5-8)工程を1つ以上経ることにより、各種態様の式(F)で表される化合物を得ることができる。これらの工程は、より具体的には下記化学反応式で示される方法により実施することができる。
また、式(F1-4)で示される(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキサミドは、粉末X線回析図形において面間隔(d)13.06、6.52、5.14、4.74、4.63、4.34、3.85、および3.72Åに特徴的なピ-クを有する結晶体として存在し、特に工業的規模で、化合物の純度が高く取り扱いやすい結晶で単離・精製されることは特に好ましいものである。
本発明で出発物質として用いる式(A)で示される(2S,5S)-1-ベンジル 2-tert-ブチル 5-ヒドロキシピペリジン-1,2-ジカルボキシレート:
のベンジルオキシカルボニル基を水素雰囲気下にて、触媒存在下、接触水素添加反応により除去して式(B)で示される(2S,5S)-tert-ブチル 5-ヒドロキシピペリジン-2-カルボキシレート:
を得ることができる。
上記で得られる式(B)の化合物を、塩基の存在下、トリフルオロアセチル化剤で処理して式(C)で示される(2S,5S)-tert-ブチル 5-ヒドロキシ-1-(2,2,2-トリフルオロアセチル)ピペリジン-2-カルボキシレート:
を得ることができる。
上記で得られる式(C)の化合物を、塩基の存在下、水酸基の活性化剤、ついでベンジルオキシアミンと反応させることにより、式(D)で示される(2S,5R)-tert-ブチル 5-(ベンジルオキシアミノ)-1-(2,2,2-トリフルオロアセチル)ピペリジン-2-カルボキシレート:
を得ることができる。
上記で得られる式(D)の化合物を、無機塩基の存在下、トリフルオロアセチル基を除去して、式(E)で示される光学活性な(2S,5R)-tert-ブチル 5-(ベンジルオキシアミノ)ピペリジン-2-カルボキシレート:
を得ることができる。
(5-1) 式(E)の化合物から式(F1)の化合物の合成
式(E)で表される化合物を、塩基の存在下、ホスゲン等価体と反応させることにより分子内ウレア化して、式(F1)で示される(2S,5R)-tert-ブチル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレートを得ることができる。
反応に用いられる塩基は、トリエチルアミン、ジイソプロピルエチルアミン、トリブチルアミン、1,8-ジアザビシクロ[5.4.0]ウンデカ-7-エン、ピリジン、2-ピコリン、2,6-ルチジン、4-ジメチルアミノピリジンから選択することができ、好ましくはトリエチルアミン、ジイソプロピルエチルアミン、またはトリブチルアミンから選択される三級アミン、4-ジメチルアミノピリジンなどの芳香族アミンである有機塩基から選択することができ、式(E)で示される化合物に対して2から4モル当量の範囲で用いられる。4-ジメチルアミノピリジンを塩基として用いる場合、式(E)で示される化合物に対して0.01から2モル当量の範囲で用いられる。
上記で得られた式(F1)の化合物の2位tert-ブチルエステルを、酸または金属塩により切断、続いてシクロヘキシルアミンを加えて、式(F1-1a)で示される(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸のシクロヘキシルアミン塩を得ることができる。
式(F1)で表される化合物の酸または金属塩によるtert-ブチルエステルの切断は、式(F1)の化合物を適当な溶媒に溶解させ、酸あるいは金属塩と処理することにより実施される。
好ましくは、蟻酸中、またはジクロロメタン中2~3モル当量の硫酸、あるいはトリフルオロ酢酸/ジクロロメタン(1/1)中で、0~+25℃で攪拌する。
なお、本工程は、Mが、シクロヘキシルアンモニウムである式(F1-1)の化合物の合成のための塩形成の工程であるが、Mがシクロヘキシルアンモニウム以外の無機カチオンまたは有機カチオンである式(F)の化合物を得る場合には、塩形成で用いられる塩基は、トリメチルアミン、トリエチルアミン、シクロヘキシルアミン、ジシクロヘキシルアミンなどのアミン類;水酸化テトラメチルアンモニウム、水酸化テトラエチルアンモニウム、水酸化テトラブチルアンモニウム、水酸化トリエチルベンジルアンモニウムなどの有機アンモニウム塩;2-エチルヘキサン酸のナトリウム、カリウム、リチウム、またはカルシウムなどのアルカリまたはアルカリ土類金属塩から選択することができる。加える塩基の当量数は、式(F1)の化合物に対して1から5モル当量から選択される。
上記で得られた式(F1-1)の化合物を、酸で処理することによりカルボン酸を遊離して、式(F1-2)で示される(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸を得ることができる。
反応に用いられる酸は、塩酸、硫酸、硫酸水素カリウム、リン酸、硝酸、またはリン酸二水素ナトリウムなどの無機酸から選択することができる。
上記で得られた式(F1-2)の化合物を、塩基、およびカルボン酸活性化剤の存在下、濃アンモニア水と反応させて、式(F1-4)で示される光学活性な(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキサミドを得る。
好ましくは、本工程は、脱水ジクロロメタン中-5から+5℃で1.2モル当量のトリエチルアミン、ジイソプロピルエチルアミン、またはトリブチルアミンから選ばれる3級アミンの存在下、1.1モル当量のクロロ蟻酸エチル、クロロ蟻酸イソブチル、またはピバル酸クロリドから選ばれる混合酸無水物化試薬を反応させた後に、5から50モル当量の濃アンモニア水と反応させる。
上記で得られた式(F1-2)で表される化合物、または後述する式(F2-2)の化合物の2位-カルボン酸をエステル化することにより、(F1-3a)で示される(2S,5R)-メチル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート:
または、式(F1-3b)で示される(2S,5R)-アリル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート:
または、式(F1-3c)で示される(2S,5R)-ベンジル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート:
または、式(F1-3d)で示される(2S,5R)-2,5-ジオキソピロリジン-1-イル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート:
を得るか、または式(F2-3):
で表される化合物を得ることができる。
上記で得た式(F1-3a)の化合物のメチルエステルを、無機塩基により加水分解して式(F1-2)の化合物を得る。
反応温度は-20から+25℃の範囲で実施される。
上記で得た式(F1-3b)で表される化合物のアリルエステルを、触媒存在下に、求核剤と反応させて切断、続いてシクロヘキシルアミンを加えて、式(F1-1a)とした後、無機酸によりカルボン酸を遊離して、式(F1-2)の化合物を得る。
本工程は好ましくは、式(F1-3b)で表される化合物を、テトラヒドロフラン、アセトニトリル、またはジクロロメタン中、室温にて0.01から0.05モル当量のパラジウムアセテート、ジクロロ-ビス(トリフェニルホスフィン)パラジウム、またはテトラキス(トリフェニルホスフィン)パラジウム存在下、1から2モル当量の2-エチルヘキサン酸ナトリウム、ピロリジン、またはジメドンと攪拌する。
上記で得られた式(F1-3d)で表される化合物を、アンモニア水と反応させて、式(F1-4)で表される化合物を得る。
本工程においては、式(F1-3d)で表される化合物を、好ましくは、脱水ジクロロメタン中-5から+5℃で5から50モル当量の濃アンモニア水と反応させる。
上記で得られた式(F1)で表される化合物のベンジル基を、接触水素添加反応により除去、続いて塩基存在下に、アリル化剤と反応させて、式(F2)で示される(2S,5R)-tert-ブチル 6-(アリルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート:
を得る。
水素添加反応に用いる溶媒は、水、メタノール、エタノール、プロパノール、イソプロパノール、ブタノール、エーテル、ジイソプロピルエーテル、酢酸エチル、酢酸ブチル、トルエン、テトラヒドロフラン、1、4-ジオキサンから選択することができ、単独あるいは混合して用いることができる。
上記水素化の工程によって得られるベンジル基の切断された6-ヒドロキシ体は、反応終了後に触媒ろ過、溶媒濃縮、溶媒交換など有機化学上汎用される通常の処理手段を採用することにより、単離することなく次工程に使用することができる。
アリル化反応の工程は、好ましくは、脱水したアセトニトリル、N,N-ジメチルホルムアミド、またはN,N-ジメチルアセトアミド中、1から2モル当量の無水炭酸ナトリウム、炭酸カリウム、炭酸セシウムから選ばれる無機塩基の存在下、1から2モル当量の臭化アリルと室温で攪拌する。
上記で得られた式(F2)の化合物の2位tert-ブチルエステルを、酸により切断、続いてシクロヘキシルアミンを加えて、式(F2-1a)で示される(2S,5R)-6-(アリルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸のシクロヘキシルアミン塩:
上記で得られた式(F2-1a)の化合物を酸で処理することによりカルボン酸を遊離して、式(F2-2):
上記で得られた式(F2-2)で表される化合物の2位-カルボン酸を、脱水縮合剤存在下にベンジルアルコールと反応させて、式(F2-3)で表される化合物の具体的化合物である式(F2-3c):
で示される(2S,5R)-ベンジル 6-(アリルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレートを得る。
(2S,5R)-tert-ブチル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート;
(2S,5R)-メチル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート;
(2S,5R)-アリル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート;
(2S,5R)-ベンジル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート;
(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸シクロヘキシルアンモニウム塩;
(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸;
(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキサミド;および
(2S,5R)-tert-ブチル 5-(ベンジルオキシアミノ)ピペリジン-2-カルボキシレート。
(2S,5S)-1-ベンジル 2-tert-ブチル 5-ヒドロキシピペリジン-1,2-ジカルボキシレート (A)
Step1: (S)-1-ベンジル 2-tert-ブチル 5-オキソピロリジン-1,2-ジカルボキシレート
(2S,5S)-tert-ブチル 5-ヒドロキシピペリジン-2-カルボキシレート (B)
(2S,5S)-tert-ブチル 5-ヒドロキシ-1-(2,2,2-トリフルオロアセチル)ピペリジン-2-カルボキシレート (C)
(2S,5R)-tert-ブチル 5-(ベンジルオキシアミノ)-1-(2,2,2-トリフルオロアセチル)ピペリジン-2-カルボキシレート (D)
(2S,5R)-tert-ブチル 5-(ベンジルオキシアミノ)ピペリジン-2-カルボキシレート (E)
(2S,5R)-tert-ブチル 5-(ベンジルオキシアミノ)ピペリジン-2-カルボキシレート(E)の連続合成
(2S,5R)-tert-ブチル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート (F1)
(2S,5R)-tert-ブチル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート (F1)
ホスゲンガスによる反応
(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸のシクロヘキシルアミン塩 (F1-1a)
(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸 (F1-2)
(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸 (F1-2)、希塩酸処理及び結晶化
(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸シクロヘキシルアミン塩を3.75g(10.0mmol)を水50mlに溶解、酢酸エチル100mlと1N塩酸20mlを加えて攪拌した後、酢酸エチル(各100ml)で3回抽出した。有機層を無水硫酸マグネシウムで乾燥,溶媒を10mlまで減圧濃縮し、氷冷下にて攪拌しながらゆっくりとヘキサン120mlを投入し生じた沈殿をろ取した。湿結晶をヘキサンで洗浄した後、室温で減圧乾燥して無色結晶性粉末の標題化合物を2.44g(8.83mmol)得た。
Mp 116℃; その他の機器データは実施例9の化合物と一致した。
(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸 (F1-2)、(F1-3a)からの合成
(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸 (F1-2)、(F1-3b)からの合成
(2S,5R)-メチル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート (F1-3a)
(2S,5R)-アリル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート (F1-3b)
(2S,5R)-ベンジル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート (F1-3c)
(2S,5R)-2,5-ジオキソピロリジン-1-イル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート (F1-3d)
(2S,5R)-tert-ブチル 6-(アリルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート (F2)
(2S,5R)-6-(アリルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸のシクロヘキシルアミン塩 (F2-1a)
(2S,5R)-6-(アリルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸 (F2-2)
(2S,5R)-ベンジル 6-(アリルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート (F2-3c)
(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキサミド (F1-4)、(F1-3d)からの合成
(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキサミド (F1-4)
(2S,5R)-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキサミド,7-オキソ-6-(スルホキシ)-モノナトリウム塩(H)
(2R,5S)-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキサミド,7-オキソ-6-(スルホキシ)-モノナトリウム塩(r)
実施例23と24で製造した化合物のβ-ラクタマーゼ酵素阻害活性とPIPCとの併用抗菌活性を測定した。被検物質の構造式は下記表14に示される通りである。
P. aeruginosa PAO1ゲノムを鋳型に、β-ラクタマーゼであるAmpCのシグナルペプチドを除く領域をコードするDNAをPCRにて増幅した。このPCR産物をpET-28b(+)ベクター(Merck)に組み込み、E. coli BL21 (Merck)に導入し、1mMのIsopropyl-β-D-(-)-thiogalactopyranoside(ナラライテスク)誘導下、20℃で一晩培養しAmpCを発現させた。菌体を回収後、超音波処理により得られた細胞抽出液から、4℃でCM Sepharose Fast Flow(GE Healthcare)およびHiTrap Heparin HP(GE Healthcare)を用いてAmpCを精製した。
P. aeruginosa PAO1から薬剤暴露により選択したAmpC構成型発現株を使用し、被検物質の細菌に対するβ-ラクタム薬との併用効果を評価した。β-ラクタム薬としてピペラシリン(PIPC、Sigma-Aldrich)を用い、PIPCの最小発育阻止濃度(MIC)をClinical and Laboratory Standards Institute(CLSI法)に準拠した寒天平板希釈法により測定した。すなわち、Mueller-Hinton agar (Becton, Dickinson and Company)に最終濃度4μg/mLの被検物質と各濃度のPIPCを含有した寒天平板を作製し、cation-adjusted Muller-Hinton broth (Becton, Dickinson and Company)で一晩培養した細菌を104CFU/spotになるように同培地で調整して、薬剤含有平板に接種した。この薬剤含有平板を35℃にて一晩培養し、菌の発育が認められない最小薬剤濃度をMICとした。その結果は表16に示される通りであった。
Claims (23)
- 無機カチオンが、ナトリウム、カリウム、リチウム、またはカルシウムを表し、
有機カチオンが、トリメチルアミン、トリエチルアミン、シクロヘキシルアミン、またはジシクロヘキシルアミンから選択されるアミンより形成されるアンモニウム塩;あるいはテトラメチルアンモニウム、テトラエチルアンモニウム、テトラブチルアンモニウム、またはトリエチルベンジルアンモニウムから選択される4級アンモニウム塩を表す、請求項1記載の光学活性な(2S,5R)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸誘導体。 - 下記式(E)で表される化合物を分子内ウレア化した後、得られた下記式(F1)で表される化合物を、少なくとも一以上の下記工程に付すことを特徴とする、請求項1で定義される式(F)で表される化合物の製造方法。
工程a エステルを切断する工程
工程b 無機カチオン、または有機カチオンの塩形態にする工程
工程c 酸処理し遊離酸にする工程
工程d カルボン酸をカルバモイル化する工程
工程e カルボン酸をエステル化する工程
工程f 6位ベンジルオキシ基のベンジル基を除去する工程
工程g 6位をアリルオキシ化する工程 - 下記のいずれかである請求項1記載の化合物:
(2S,5R)-tert-ブチル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート、
(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸シクロヘキシルアミン塩、
(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸、
(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキサミド、
(2S,5R)-メチル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート、
(2S,5R)-アリル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート、
(2S,5R)-ベンジル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート、
(2S,5R)-2,5-ジオキソピロリジン-1-イル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート、
(2S,5R)-tert-ブチル 6-(アリルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート、
(2S,5R)-6-(アリルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸シクロヘキシルアミン塩、
(2S,5R)-6-(アリルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸、
(2S,5R)-ベンジル 6-(アリルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレート。 - 粉末X線回折図形において、面間隔(d)11.56、10.96、6.55、6.00、5.79、5.56、5.47、5.25、4.90,4.35,4.23、及び3.86Åに特徴的なピ-クを有する(2S,5R)-tert-ブチル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレートの結晶。
- 粉末X線回折図形において、面間隔(d)10.39、5.86、5.69、5.34、4.81、4.44、3.98、3.78、3.11、3.03、2.93、及び2.77Åに特徴的なピ-クを有する(2S,5R)-メチル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレートの結晶。
- 粉末X線回折図形において、面間隔(d)14.72、4.91、4.46、4.24、及び3.67Åに特徴的なピ-クを有する(2S,5R)-アリル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレートの結晶。
- 粉末X線回折図形において、面間隔(d)9.95、8.45、6.26、5.87、5.52、5.22、5.10、4.96、4.73、4.54、4.16、3.93、及び3.55Åに特徴的なピ-クを有する(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸シクロヘキシルアンモニウム塩の結晶。
- 粉末X線回折図形において、面間隔(d)8.19、7.14、6.64、6.29、5.60、5.21、4.91、4.60、4.21、3.69、3.45、および3.13Åに特徴的なピ-クを有する(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸の結晶。
- 粉末X線回折図形において、面間隔(d)13.06、6.52、5.14、4.74、4.63、4.34、3.85、及び3.72Åに特徴的なピ-クを有する(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキサミドの結晶。
- (2S,5R)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸誘導体を含有するβ-ラクタマーゼ阻害剤を配合した感染症治療薬を製造するための(2S,5R)-tert-ブチル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレートの使用。
- (2S,5R)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸誘導体を含有するβ-ラクタマーゼ阻害剤を配合した感染症治療薬を製造するための(2S,5R)-メチル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレートの使用。
- (2S,5R)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸誘導体を含有するβ-ラクタマーゼ阻害剤を配合した感染症治療薬を製造するための(2S,5R)-アリル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレートの使用。
- (2S,5R)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸誘導体を含有するβ-ラクタマーゼ阻害剤を配合した感染症治療薬を製造するための(2S,5R)-ベンジル 6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキシレートの使用。
- (2S,5R)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸誘導体を含有するβ-ラクタマーゼ阻害剤を配合した感染症治療薬を製造するための(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸シクロヘキシルアンモニウム塩の使用。
- (2S,5R)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸誘導体を含有するβ-ラクタマーゼ阻害剤を配合した感染症治療薬を製造するための(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸の使用。
- (2S,5R)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸誘導体を含有するβ-ラクタマーゼ阻害剤を配合した感染症治療薬を製造するための(2S,5R)-6-(ベンジルオキシ)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボキサミドの使用。
- (2S,5R)-7-オキソ-1,6-ジアザビシクロ[3.2.1]オクタン-2-カルボン酸誘導体を含有するβ-ラクタマーゼ阻害剤を配合した感染症治療薬を製造するための(2S,5R)-tert-ブチル 5-(ベンジルオキシアミノ)ピペリジン-2-カルボキシレートの使用。
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI201131101A SI2657234T1 (sl) | 2010-12-22 | 2011-06-30 | Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo |
EP11850585.8A EP2657234B1 (en) | 2010-12-22 | 2011-06-30 | Optically-active diazabicyclooctane derivative and method for manufacturing same |
DK11850585.8T DK2657234T3 (da) | 2010-12-22 | 2011-06-30 | Optisk aktivt diazabicyclooctanderivat og fremgangsmåde til fremstilling heraf |
ES11850585.8T ES2622004T3 (es) | 2010-12-22 | 2011-06-30 | Derivado de diazabiciclooctano ópticamente activo y método para preparar el mismo |
KR1020137018996A KR101836554B1 (ko) | 2010-12-22 | 2011-06-30 | 광학 활성인 디아자비시클로옥탄 유도체 및 그의 제조법 |
CA2822758A CA2822758C (en) | 2010-12-22 | 2011-06-30 | Optically active diazabicyclooctane derivative and process for preparing the same |
AU2011346224A AU2011346224B2 (en) | 2010-12-22 | 2011-06-30 | Optically-active diazabicyclooctane derivative and method for manufacturing same |
JP2012549653A JP5903386B2 (ja) | 2010-12-22 | 2011-06-30 | 光学活性なジアザビシクロオクタン誘導体およびその製造法 |
CN201180061822.5A CN103328476B (zh) | 2010-12-22 | 2011-06-30 | 光学活性二氮杂环辛烷衍生物及其制备方法 |
RU2013133870/04A RU2591701C2 (ru) | 2010-12-22 | 2011-06-30 | Оптически активное производное диазабициклооктана и способ его получения |
SG2013048582A SG191320A1 (en) | 2010-12-22 | 2011-06-30 | Optically-active diazabicyclooctane derivative and method for manufacturing same |
IL227087A IL227087A0 (en) | 2010-12-22 | 2013-06-20 | (2s,5r)-6-(benzyloxy/allyloxy)-7-oxo-6,1-diazabicyclo[1.2.3]octane-2-carboxylates, process for their preparation and use of (2s,5r)-tert-butyl-6 -(benzyloxy)-7-oxo-6,1-diazabicyclo[1.2.3]octane-2-carboxylate for the preparation of an anti-infective drug |
IL238032A IL238032A (en) | 2010-12-22 | 2015-03-30 | A process for making a compound useful for the production of a Diaz-bicyclo-octane optically active history |
IL243939A IL243939A0 (en) | 2010-12-22 | 2016-02-03 | 2s,5r))-6)-(benzyloxy/allyloxy)-7-oxo-1,6-diazabicyclo[3.2.1.]octane-2-carboxylates, methods for their preparation and use of (2s,5r)-tert-butyl -6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate for the preparation of anti-infective drugs |
IL244239A IL244239B (en) | 2010-12-22 | 2016-02-22 | Process for the preparation of (s2,r5)-6-(benzyl/allyl)oxy-7-oxo-6,1-diazabicyclo[1.2.3]octane-2-carboxylic acid, and also its esters and salts |
IL248246A IL248246B (en) | 2010-12-22 | 2016-10-09 | (5r,2s)-6-(benzyloxy/allyloxy)-7-oxo-6,1-diazabicyclo[1.2.3]octane-2-carboxylates, process for their preparation and use of (5r,2s)-tert-butyl-6 -(benzyloxy)-7-oxo-6,1-diazabicyclo[1.2.3]octane-2-carboxylate for the preparation of anti-infective drugs |
AU2017203187A AU2017203187B2 (en) | 2010-12-22 | 2017-05-12 | Optically-active diazabicyclooctane derivative and method for manufacturing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010073093 | 2010-12-22 | ||
JPPCT/JP2010/073093 | 2010-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012086241A1 true WO2012086241A1 (ja) | 2012-06-28 |
Family
ID=46313528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/065001 WO2012086241A1 (ja) | 2010-12-22 | 2011-06-30 | 光学活性なジアザビシクロオクタン誘導体およびその製造法 |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP2657234B1 (ja) |
JP (3) | JP5903386B2 (ja) |
KR (1) | KR101836554B1 (ja) |
CN (2) | CN104892490B (ja) |
AR (1) | AR116907A2 (ja) |
AU (2) | AU2011346224B2 (ja) |
CA (1) | CA2822758C (ja) |
DK (1) | DK2657234T3 (ja) |
ES (1) | ES2622004T3 (ja) |
HK (1) | HK1210153A1 (ja) |
HU (1) | HUE032491T2 (ja) |
IL (5) | IL227087A0 (ja) |
PL (1) | PL2657234T3 (ja) |
RU (1) | RU2591701C2 (ja) |
SG (2) | SG191320A1 (ja) |
SI (1) | SI2657234T1 (ja) |
TW (1) | TWI599355B (ja) |
WO (1) | WO2012086241A1 (ja) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014517027A (ja) * | 2011-06-17 | 2014-07-17 | アストラゼネカ アクチボラグ | trans−7−オキソ−6−(スルホオキシ)−1,6−ジアザビシクロ[3,2,1]オクタン−2−カルボキサミドとその塩が含まれる複素環式化合物を製造するための方法 |
WO2014135931A1 (en) * | 2013-03-08 | 2014-09-12 | Wockhardt Limited | A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane |
WO2014135930A1 (en) * | 2013-03-08 | 2014-09-12 | Wockhardt Limited | A process for sodium salt of (2s, 5r)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane |
WO2014135932A1 (en) * | 2013-03-08 | 2014-09-12 | Wockhardt Limited | A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane |
US8916709B2 (en) | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
US8927724B2 (en) | 2012-03-30 | 2015-01-06 | Cubist Pharmaceuticals, Inc. | Isoxazole beta-lactamase inhibitors |
US8933232B2 (en) | 2012-03-30 | 2015-01-13 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
US8969570B2 (en) | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
WO2015033191A1 (en) * | 2013-03-08 | 2015-03-12 | Wockhardt Limited | A process for preparation of (2s, 5r)- sulfuric acid mono-{[(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester |
WO2015046207A1 (ja) * | 2013-09-24 | 2015-04-02 | Meiji Seikaファルマ株式会社 | ジアザビシクロオクタン誘導体の製造法とその中間体 |
CN104768930A (zh) * | 2012-11-01 | 2015-07-08 | 株式会社钟化 | 光学活性双环脲化合物的制造方法 |
US9120795B2 (en) | 2013-03-14 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | Crystalline form of a β-lactamase inhibitor |
US9120796B2 (en) | 2013-10-02 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
CN105143225A (zh) * | 2013-03-08 | 2015-12-09 | 沃克哈特有限公司 | 一种制备(2s,5r)-7-氧代-6-磺酰氧基-2-[((3r)-哌啶-3-羰基)-肼基羰基]-1,6-二氮杂-双环[3.2.1]辛烷的方法 |
JP2016511269A (ja) * | 2013-03-08 | 2016-04-14 | ウォックハート リミテッド | (2s,5r)−6−ベンジルオキシ−7−オキソ−1,6−ジアザ−ビシクロ[3.2.1]オクタン−2−カルボン酸のナトリウム塩およびその調製 |
US9676777B2 (en) | 2010-12-22 | 2017-06-13 | Meiji Seika Pharma Co., Ltd. | Compounds useful for producing an optically active diazabicyclooctane compound |
CN106866668A (zh) * | 2017-01-23 | 2017-06-20 | 齐鲁天和惠世制药有限公司 | 一锅法制备阿维巴坦钠的方法 |
US9708320B2 (en) | 2012-05-30 | 2017-07-18 | Meiji Seika Pharma Co., Ltd. | β-lactamase inhibitor and process for preparing the same |
US10085999B1 (en) | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
JP2018528939A (ja) * | 2015-08-10 | 2018-10-04 | サンド・アクチエンゲゼルシヤフト | アビバクタムナトリウムのc形 |
US10131665B2 (en) | 2013-10-08 | 2018-11-20 | Meiji Seika Pharma Co., Ltd. | Processes for producing diazabicyclooctane compounds |
WO2019075984A1 (zh) | 2017-10-18 | 2019-04-25 | 新发药业有限公司 | 一种阿维巴坦中间体的制备方法 |
WO2019075990A1 (zh) | 2017-10-18 | 2019-04-25 | 新发药业有限公司 | 一种阿维巴坦中间体的简便制备方法 |
WO2019093450A1 (ja) * | 2017-11-10 | 2019-05-16 | 塩野義製薬株式会社 | ジアザビシクロオクタン誘導体 |
US10294224B2 (en) | 2014-12-05 | 2019-05-21 | Meiji Seika Pharma Co., Ltd. | Lyophilized composition of a diazabicyclooctane compound and process of producing the same |
WO2019105479A1 (zh) | 2017-12-01 | 2019-06-06 | 南京明德新药研发股份有限公司 | 一种β-内酰胺酶抑制剂的晶型及其制备方法 |
WO2019127903A1 (zh) | 2017-12-25 | 2019-07-04 | 新发药业有限公司 | 一种阿维巴坦的简便制备方法 |
US10815228B2 (en) | 2017-10-02 | 2020-10-27 | Arixa Pharmaceuticals, Inc. | Aztreonam derivatives and uses thereof |
US11008321B2 (en) | 2019-03-12 | 2021-05-18 | Arixa Pharmaceuticals, Inc. | Crystalline form of an avibactam derivative |
US11180500B2 (en) | 2018-10-01 | 2021-11-23 | Arixa Pharmaceuticals, Inc. | Derivatives of relebactam and uses thereof |
US11565999B2 (en) | 2019-04-25 | 2023-01-31 | Arixa Pharmaceuticals, Inc. | Methods of synthesizing aztreonam derivatives |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104892490B (zh) * | 2010-12-22 | 2017-07-21 | 明治制果药业株式会社 | 用于制备光学活性二氮杂环辛烷衍生物的中间体化合物的化合物 |
US9663518B1 (en) | 2014-02-03 | 2017-05-30 | Wockhardt Limited | Process for preparation of (2S, 5R)-1,6-diaza-bicyclo[3.2.1]octane-2-carbonitrile-7-oxo-6-(sulfooxy)-mono sodium salt |
EP3126363A1 (en) * | 2014-03-29 | 2017-02-08 | Wockhardt Limited | A process for preparation of sodium (2s, 5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate |
CN107325096B (zh) * | 2016-04-29 | 2020-11-03 | 正大天晴药业集团股份有限公司 | 一种阿维巴坦单钠盐的结晶 |
CN106565712A (zh) * | 2016-09-30 | 2017-04-19 | 天津津泰生物医药技术有限公司 | 一种阿维巴坦钠中间体的制备方法 |
CN106699756B (zh) * | 2016-12-30 | 2019-10-29 | 淄博鑫泉医药技术服务有限公司 | β内酰胺酶抑制剂阿维巴坦的合成方法 |
CN106831772B (zh) * | 2017-03-04 | 2019-12-17 | 丽珠医药集团股份有限公司 | 一种阿维巴坦中间体的合成方法 |
WO2018234962A1 (en) * | 2017-06-20 | 2018-12-27 | Wockhardt Limited | PROCESS FOR O-SULFONATION OF 1,6-DIAZABICYCLO [3.2.1] OCTANE COMPOUNDS |
CN109400521B (zh) * | 2017-08-18 | 2020-05-08 | 新发药业有限公司 | 一种改进的5r-苄氧氨基哌啶-2s-甲酸酯、其草酸盐的制备方法 |
CN107417686B (zh) * | 2017-09-19 | 2020-04-28 | 北京化工大学 | 一种阿维巴坦钠的合成方法 |
TWI826399B (zh) | 2017-11-03 | 2023-12-21 | 瑞士商愛爾康公司 | 氮雜雙環和二氮呯衍生物 |
CN107941969B (zh) * | 2017-11-07 | 2021-03-02 | 中山奕安泰医药科技有限公司 | (2s,5r)-苯氧胺基哌啶-2-甲酰胺的检测方法 |
CN107894471A (zh) * | 2017-11-07 | 2018-04-10 | 中山奕安泰医药科技有限公司 | 一种阿维巴坦钠中间体的检测方法 |
CN107907604B (zh) * | 2017-11-07 | 2021-01-22 | 中山奕安泰医药科技有限公司 | (2s,5r)-苯氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法 |
CN107941944B (zh) * | 2017-11-23 | 2020-09-15 | 中山奕安泰医药科技有限公司 | 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法 |
CN109970625B (zh) * | 2017-12-28 | 2021-02-26 | 新发药业有限公司 | 一种5r-苄氧氨基哌啶-2s-甲酸或其衍生物的制备方法 |
US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
CN111777607A (zh) * | 2020-07-21 | 2020-10-16 | 海南海灵化学制药有限公司 | 一种阿维巴坦纳的制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002010172A1 (fr) * | 2000-08-01 | 2002-02-07 | Aventis Pharma Sa | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
WO2003063864A2 (fr) * | 2002-01-28 | 2003-08-07 | Aventis Pharma S.A. | Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
WO2009091856A2 (en) | 2008-01-18 | 2009-07-23 | Merck & Co., Inc. | Beta-lactamase inhibitors |
WO2009090320A1 (fr) * | 2007-09-14 | 2009-07-23 | Novexel | Procede de preparation d'une piperidine disubstituee et intermediaires |
WO2009133442A1 (fr) | 2008-04-29 | 2009-11-05 | Novexel | Composes azabiycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamase |
EP2135959A1 (en) | 2008-06-19 | 2009-12-23 | Novexel | Use of (1R,2S,5R) 1,6-Diazabicyclo [3,2,1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases |
WO2010126820A2 (en) | 2009-04-30 | 2010-11-04 | Merck Sharp & Dohme Corp. | Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ282567B6 (cs) * | 1993-12-29 | 1997-08-13 | Pfizer Inc. | Diazabicyklické sloučeniny a farmaceutické prostředky na jejich bázi |
FR2951171A1 (fr) * | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
CN104892490B (zh) * | 2010-12-22 | 2017-07-21 | 明治制果药业株式会社 | 用于制备光学活性二氮杂环辛烷衍生物的中间体化合物的化合物 |
-
2011
- 2011-06-30 CN CN201510212878.6A patent/CN104892490B/zh active Active
- 2011-06-30 SI SI201131101A patent/SI2657234T1/sl unknown
- 2011-06-30 JP JP2012549653A patent/JP5903386B2/ja active Active
- 2011-06-30 HU HUE11850585A patent/HUE032491T2/en unknown
- 2011-06-30 ES ES11850585.8T patent/ES2622004T3/es active Active
- 2011-06-30 EP EP11850585.8A patent/EP2657234B1/en active Active
- 2011-06-30 PL PL11850585T patent/PL2657234T3/pl unknown
- 2011-06-30 DK DK11850585.8T patent/DK2657234T3/da active
- 2011-06-30 WO PCT/JP2011/065001 patent/WO2012086241A1/ja active Application Filing
- 2011-06-30 SG SG2013048582A patent/SG191320A1/en unknown
- 2011-06-30 TW TW100123062A patent/TWI599355B/zh active
- 2011-06-30 CN CN201180061822.5A patent/CN103328476B/zh active Active
- 2011-06-30 RU RU2013133870/04A patent/RU2591701C2/ru active
- 2011-06-30 KR KR1020137018996A patent/KR101836554B1/ko active IP Right Grant
- 2011-06-30 SG SG10201510576WA patent/SG10201510576WA/en unknown
- 2011-06-30 AU AU2011346224A patent/AU2011346224B2/en not_active Ceased
- 2011-06-30 CA CA2822758A patent/CA2822758C/en active Active
-
2013
- 2013-06-20 IL IL227087A patent/IL227087A0/en active IP Right Grant
-
2015
- 2015-03-30 IL IL238032A patent/IL238032A/en active IP Right Grant
- 2015-11-04 HK HK15110896.7A patent/HK1210153A1/xx unknown
-
2016
- 2016-01-13 JP JP2016004539A patent/JP6364431B2/ja active Active
- 2016-02-03 IL IL243939A patent/IL243939A0/en active IP Right Grant
- 2016-02-22 IL IL244239A patent/IL244239B/en active IP Right Grant
- 2016-10-09 IL IL248246A patent/IL248246B/en active IP Right Grant
-
2017
- 2017-05-12 AU AU2017203187A patent/AU2017203187B2/en not_active Ceased
- 2017-08-15 JP JP2017156787A patent/JP2018009008A/ja active Pending
-
2019
- 2019-12-12 AR ARP190103632A patent/AR116907A2/es unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002010172A1 (fr) * | 2000-08-01 | 2002-02-07 | Aventis Pharma Sa | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
US7112592B2 (en) | 2000-08-01 | 2006-09-26 | Aventis Pharma S.A. | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
WO2003063864A2 (fr) * | 2002-01-28 | 2003-08-07 | Aventis Pharma S.A. | Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
US7612087B2 (en) | 2002-01-28 | 2009-11-03 | Novexel | Heterocyclic compounds as inhibitors of beta-lactamases |
WO2009090320A1 (fr) * | 2007-09-14 | 2009-07-23 | Novexel | Procede de preparation d'une piperidine disubstituee et intermediaires |
US20100197928A1 (en) | 2007-09-14 | 2010-08-05 | Novexel | Method for preparing disubstituted piperidine and intermediates |
WO2009091856A2 (en) | 2008-01-18 | 2009-07-23 | Merck & Co., Inc. | Beta-lactamase inhibitors |
WO2009133442A1 (fr) | 2008-04-29 | 2009-11-05 | Novexel | Composes azabiycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamase |
EP2135959A1 (en) | 2008-06-19 | 2009-12-23 | Novexel | Use of (1R,2S,5R) 1,6-Diazabicyclo [3,2,1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases |
WO2010126820A2 (en) | 2009-04-30 | 2010-11-04 | Merck Sharp & Dohme Corp. | Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids |
Non-Patent Citations (17)
Title |
---|
BALDWIN, JE.; ADLINGTON, RM.; GODFREY, CRA.; GOLLINS, DW.; VAUGHAN, JG.: "A Novel Entry to Carbenoid Species via P-Ketosulfbxonium Ylides", JOURNAL OF THE CHEMICAL SOCIETY CHEMICAL COMMUNICATIONS, 1993, pages 1434 - 1435, XP009135902 |
CARTWRIGHT, D. ET AL.: "Synthesis of DL- slaframine", J. AM. CHEM. SOC., vol. 92, no. 26, 1970, pages 7615 - 7, XP002412497 * |
DOLENCE, EK.; LIN, CE.; MILLER, MJ.; PAYNE, SM.: "Synthesis and siderophore activity of albomycin-like peptides derived from N5-acetyl-N5- hydroxy-L-ornithine", JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, no. 3, 1991, pages 956 - 968, XP055153634, DOI: doi:10.1021/jm00107a013 |
FREED, ME.; DAY AR.: "Synthesis of 5-Ketopipecolic Acid from Glutamic Acid", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 25, no. 12, 1960, pages 2105 - 2107 |
HOARAU, S. ET AL.: "Synthesis of enantiomerically pure (2R,5S)- and (2R,5R)-5- hydroxypipecolic acid from glycinate schif bases", TETRAHEDRON: ASYMMETRY, vol. 7, no. 9, 1996, pages 2585 - 93, XP004048331 * |
J. CHEM. SOC., CHEM. COMMUN., 1993, pages 1434 |
JUNG, J. C. ET AL.: "Diastereoselective synthesis of (2S,5S)- and (2S,5R)-N- benzyloxycarbonyl-5-hydroxypipecolic acids from trans-4-hydroxy-L-proline", TETRAHEDRON: ASYMMETRY, vol. 17, no. 17, 2006, pages 2479 - 86, XP024962414 * |
JUNG, JC.; AVERY, MA.: "Diastereoselective synthesis of (2S,5S)- and (2S,5R)-N-benzyloxycarbonyl-5-hydroxypipecolic acids from trans-4- hydroxy-L-proline", TETRAHEDRON ASYMMETRY, vol. 17, no. 17, 2006, pages 2479 - 2486, XP024962414, DOI: doi:10.1016/j.tetasy.2006.07.035 |
KING, FE.; KING, TJ.; WARWICK, AJ.: "The Chemistry of Extractives from Hardwoods. Part III. Baikiain, an Amino-acid Present in Baikiaea plurijuga", JOURNAL OF THE CHEMICAL SOCIETY, 1950, pages 3590 - 3597 |
KO, K. Y. ET AL.: "A convenient synthesis of 5-oxo-L-pipecolic acid derivative from L- glutamic acid", BULLETIN- KOREAN CHEMICAL SOCIETY 0253-2964 (TIB), vol. 16, no. 6, 1995, pages 565 - 567, XP008169513 * |
LONKAR, P. S. ET AL.: "trans-5-Aminopipecolyl- aegPNA chimera: design, synthesis, and study of binding preferences with DNA/RNA in duplex/ triplex mode", J. ORG. CHEM., vol. 70, no. 17, 2005, pages 6956 - 9, XP055118264 * |
MANGION, IK.; NWAMBA, IK.; SHEVLIN, M.; HUFFMAN MA.: "Iridium-Catalyzed X-H Insertions of Sulfoxonium Ylides", ORGANIC LETTERS, vol. 11, no. 16, 2009, pages 3566 - 3569 |
ORG. LETT., vol. 11, no. 16, 2009, pages 3566 - 3569 |
SCHNEIDER, M. J. ET AL.: "Synthesis of slaframine", J. ORG. CHEM., vol. 49, no. 20, 1984, pages 3681 - 4, XP000983198 * |
See also references of EP2657234A4 |
TETRAHEDRON ASYMMETRY, vol. 17, no. 17, 2006, pages 2479 - 2486 |
WITKOP, B.; FOLTS, CM.: "The Configuration of 5- Hydroxypipecolic Acid from Dates", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 79, no. 1, 1957, pages 192 - 197 |
Cited By (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9676777B2 (en) | 2010-12-22 | 2017-06-13 | Meiji Seika Pharma Co., Ltd. | Compounds useful for producing an optically active diazabicyclooctane compound |
JP2014517027A (ja) * | 2011-06-17 | 2014-07-17 | アストラゼネカ アクチボラグ | trans−7−オキソ−6−(スルホオキシ)−1,6−ジアザビシクロ[3,2,1]オクタン−2−カルボキサミドとその塩が含まれる複素環式化合物を製造するための方法 |
JP2017036307A (ja) * | 2011-06-17 | 2017-02-16 | アストラゼネカ アクチボラグ | trans−7−オキソ−6−(スルホオキシ)−1,6−ジアザビシクロ[3,2,1]オクタン−2−カルボキサミドとその塩が含まれる複素環式化合物を製造するための方法 |
US8940897B2 (en) | 2012-03-30 | 2015-01-27 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors |
US8962843B2 (en) | 2012-03-30 | 2015-02-24 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
US8927724B2 (en) | 2012-03-30 | 2015-01-06 | Cubist Pharmaceuticals, Inc. | Isoxazole beta-lactamase inhibitors |
US8933232B2 (en) | 2012-03-30 | 2015-01-13 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
US8933233B2 (en) | 2012-03-30 | 2015-01-13 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors |
US8969570B2 (en) | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
US8962844B2 (en) | 2012-03-30 | 2015-02-24 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors |
US8916709B2 (en) | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
US10023573B2 (en) | 2012-05-30 | 2018-07-17 | Meiji Seika Pharma Co., Ltd. | Beta-lactamase inhibitor and process for preparing the same |
US10556905B2 (en) | 2012-05-30 | 2020-02-11 | Meiji Seika Pharma Co., Ltd. | Processes for preparing a diazabicyclooctane compound |
US9708320B2 (en) | 2012-05-30 | 2017-07-18 | Meiji Seika Pharma Co., Ltd. | β-lactamase inhibitor and process for preparing the same |
US11117896B2 (en) | 2012-05-30 | 2021-09-14 | Meiji Seika Pharma Co., Ltd. | Processes for preparing a diazabicyclooctane compound |
US11731971B2 (en) | 2012-05-30 | 2023-08-22 | Meiji Seika Pharma Co., Ltd. | Processes for preparing a diazabicyclooctane compound |
JPWO2014069351A1 (ja) * | 2012-11-01 | 2016-09-08 | 株式会社カネカ | 光学活性二環式ウレア化合物の製造方法 |
CN104768930A (zh) * | 2012-11-01 | 2015-07-08 | 株式会社钟化 | 光学活性双环脲化合物的制造方法 |
KR101763056B1 (ko) * | 2013-03-08 | 2017-07-28 | 욱크하르트 리미티드 | (2s,5r)-2-카복스아미도-7-옥소-6-설포옥시-1,6-디아자-비사이클로[3.2.1]옥탄의 나트륨염을 위한 방법 |
CN105143224A (zh) * | 2013-03-08 | 2015-12-09 | 沃克哈特有限公司 | 一种制备(2s,5r)-硫酸单-{[(4-氨基哌啶-4-基)羰基]-7-氧代-1,6-二氮杂-双环[3.2.1]-辛-6-基}酯的方法 |
US20160002233A1 (en) * | 2013-03-08 | 2016-01-07 | Wockhardt Limited | (2S, 5R)- Sulfuric acid mono- ester |
US20160016955A1 (en) * | 2013-03-08 | 2016-01-21 | Wockhardt Limited | A process for sodium salt of (2S, 5R)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane |
JP2016510062A (ja) * | 2013-03-08 | 2016-04-04 | ウォックハート リミテッド | (2s,5r)−2−カルボキシアミド−7−オキソ−6−スルホオキシ−1,6−ジアザ−ビシクロ[3.2.1]オクタンのナトリウム塩のためのプロセス |
JP2016510063A (ja) * | 2013-03-08 | 2016-04-04 | ウォックハート リミテッド | (2s,5r)−硫酸モノ−{[(4−アミノピペリジン−4−イル)カルボニル]−7−オキソ−1,6−ジアザ−ビシクロ[3.2.1]オクタ−6−イル}エステルを調製するための方法 |
JP2016511269A (ja) * | 2013-03-08 | 2016-04-14 | ウォックハート リミテッド | (2s,5r)−6−ベンジルオキシ−7−オキソ−1,6−ジアザ−ビシクロ[3.2.1]オクタン−2−カルボン酸のナトリウム塩およびその調製 |
WO2014135931A1 (en) * | 2013-03-08 | 2014-09-12 | Wockhardt Limited | A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane |
JP2016514107A (ja) * | 2013-03-08 | 2016-05-19 | ウォックハート リミテッド | (2s,5r)−7−オキソ−6−スルホオキシ−2−[((3r)−ピペリジン−3−カルボニル)−ヒドラジノカルボニル]−1,6−ジアザ−ビシクロ[3.2.1]オクタンの調製のためのプロセス |
WO2014135930A1 (en) * | 2013-03-08 | 2014-09-12 | Wockhardt Limited | A process for sodium salt of (2s, 5r)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane |
JP2016515102A (ja) * | 2013-03-08 | 2016-05-26 | ウォックハート リミテッド | (2s,5r)−7−オキソ−6−スルホオキシ−2−[((3r)−ピロリジン−3−カルボニル)−ヒドラジノカルボニル]−1,6−ジアザ−ビシクロ[3.2.1]オクタンの調製のためのプロセス |
KR101780577B1 (ko) * | 2013-03-08 | 2017-09-21 | 욱크하르트 리미티드 | (2s, 5r)-황산 모노-{[(4-아미노피페리딘-4-일)카보닐]-7-옥소-1,6-디아자-비사이클로[3.2.1]-옥트-6-일}에스테르의 제조 방법 |
US9556174B2 (en) | 2013-03-08 | 2017-01-31 | Wockhardt Limited | (2S, 5R)-sulfuric acid mono-{[(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester |
US9567335B2 (en) * | 2013-03-08 | 2017-02-14 | Wockhardt Limited | Process for sodium salt of (2S, 5R)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane |
CN105143226A (zh) * | 2013-03-08 | 2015-12-09 | 沃克哈特有限公司 | 制备(2s,5r)-2-甲酰胺基-7-氧代-6-磺酰氧基-1,6-二氮杂-双环[3.2.1]辛烷的钠盐的方法 |
WO2014135932A1 (en) * | 2013-03-08 | 2014-09-12 | Wockhardt Limited | A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane |
US9657021B2 (en) | 2013-03-08 | 2017-05-23 | Wockhardt Limited | Process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2[((3R)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]-octane |
WO2015033191A1 (en) * | 2013-03-08 | 2015-03-12 | Wockhardt Limited | A process for preparation of (2s, 5r)- sulfuric acid mono-{[(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester |
CN105143225A (zh) * | 2013-03-08 | 2015-12-09 | 沃克哈特有限公司 | 一种制备(2s,5r)-7-氧代-6-磺酰氧基-2-[((3r)-哌啶-3-羰基)-肼基羰基]-1,6-二氮杂-双环[3.2.1]辛烷的方法 |
KR101774133B1 (ko) | 2013-03-08 | 2017-09-01 | 욱크하르트 리미티드 | (2s, 5r)-7-옥소-6-술포옥시-2-[((3r)-피롤리딘-3-카보닐)-히드라지노 카보닐]-1,6-디아자-비사이클로[3.2.1]옥탄의 제조 방법 |
JP2018058894A (ja) * | 2013-03-08 | 2018-04-12 | ウォックハート リミテッド | (2s,5r)−6−ベンジルオキシ−7−オキソ−1,6−ジアザ−ビシクロ[3.2.1]オクタン−2−カルボン酸のナトリウム塩 |
US9834557B2 (en) | 2013-03-08 | 2017-12-05 | Wockhardt Limited | Process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2-[((3R)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]-octane |
US9120795B2 (en) | 2013-03-14 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | Crystalline form of a β-lactamase inhibitor |
US10000492B2 (en) | 2013-09-24 | 2018-06-19 | Meiji Seika Pharma Co., Ltd. | Process for producing diazabicyclooctane derivative |
JPWO2015046207A1 (ja) * | 2013-09-24 | 2017-03-09 | Meiji Seikaファルマ株式会社 | ジアザビシクロオクタン誘導体の製造法とその中間体 |
CN107501264A (zh) * | 2013-09-24 | 2017-12-22 | 明治制果药业株式会社 | 二氮杂二环辛烷衍生物的制备方法 |
AU2014324302B2 (en) * | 2013-09-24 | 2018-02-15 | Meiji Seika Pharma Co., Ltd. | Production method for diazabicyclooctane derivative and intermediary body thereof |
WO2015046207A1 (ja) * | 2013-09-24 | 2015-04-02 | Meiji Seikaファルマ株式会社 | ジアザビシクロオクタン誘導体の製造法とその中間体 |
CN105555787B (zh) * | 2013-09-24 | 2017-08-08 | 明治制果药业株式会社 | 二氮杂二环辛烷衍生物的制备方法及其中间体 |
US10000491B2 (en) | 2013-09-24 | 2018-06-19 | Meiji Seika Pharma Co., Ltd. | Process for producing diazabicyclooctane derivative and intermediate thereof |
CN105555787A (zh) * | 2013-09-24 | 2016-05-04 | 明治制果药业株式会社 | 二氮杂二环辛烷衍生物的制备方法及其中间体 |
KR102239725B1 (ko) | 2013-09-24 | 2021-04-12 | 메이지 세이카 파루마 가부시키가이샤 | 디아자비시클로옥탄 유도체의 제조법과 그의 중간체 |
TWI644908B (zh) * | 2013-09-24 | 2018-12-21 | 明治製菓藥業股份有限公司 | 二氮雜二環辛烷衍生物之製法及其中間體 |
KR20160058851A (ko) * | 2013-09-24 | 2016-05-25 | 메이지 세이카 파루마 가부시키가이샤 | 디아자비시클로옥탄 유도체의 제조법과 그의 중간체 |
US9120796B2 (en) | 2013-10-02 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
US10131665B2 (en) | 2013-10-08 | 2018-11-20 | Meiji Seika Pharma Co., Ltd. | Processes for producing diazabicyclooctane compounds |
US11414417B2 (en) | 2013-10-08 | 2022-08-16 | Meiji Seika Pharma Co., Ltd. | Crystalline forms of diazabicyclooctane derivative and production process thereof |
US10604522B2 (en) | 2013-10-08 | 2020-03-31 | Meiji Seika Pharma Co., Ltd. | Processes for producing diazabicyclooctane compounds |
US11117895B2 (en) | 2014-12-05 | 2021-09-14 | Meiji Seika Pharma Co., Ltd. | Process for producing crystals of a diazabicyclooctane derivative |
US10294224B2 (en) | 2014-12-05 | 2019-05-21 | Meiji Seika Pharma Co., Ltd. | Lyophilized composition of a diazabicyclooctane compound and process of producing the same |
JP2018528939A (ja) * | 2015-08-10 | 2018-10-04 | サンド・アクチエンゲゼルシヤフト | アビバクタムナトリウムのc形 |
JP7075884B2 (ja) | 2015-08-10 | 2022-05-26 | サンド・アクチエンゲゼルシヤフト | アビバクタムナトリウムのc形 |
CN106866668A (zh) * | 2017-01-23 | 2017-06-20 | 齐鲁天和惠世制药有限公司 | 一锅法制备阿维巴坦钠的方法 |
US10085999B1 (en) | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
US10500211B2 (en) | 2017-05-10 | 2019-12-10 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
US10722521B2 (en) | 2017-05-10 | 2020-07-28 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
WO2018208557A1 (en) | 2017-05-10 | 2018-11-15 | Arixa Pharmaceuticals, Inc. | 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections |
US10815228B2 (en) | 2017-10-02 | 2020-10-27 | Arixa Pharmaceuticals, Inc. | Aztreonam derivatives and uses thereof |
WO2019075990A1 (zh) | 2017-10-18 | 2019-04-25 | 新发药业有限公司 | 一种阿维巴坦中间体的简便制备方法 |
WO2019075984A1 (zh) | 2017-10-18 | 2019-04-25 | 新发药业有限公司 | 一种阿维巴坦中间体的制备方法 |
WO2019093450A1 (ja) * | 2017-11-10 | 2019-05-16 | 塩野義製薬株式会社 | ジアザビシクロオクタン誘導体 |
WO2019105479A1 (zh) | 2017-12-01 | 2019-06-06 | 南京明德新药研发股份有限公司 | 一种β-内酰胺酶抑制剂的晶型及其制备方法 |
US11180501B2 (en) | 2017-12-01 | 2021-11-23 | Qilu Pharmaceutical Co., Ltd. | Crystal form of β-lactamase inhibitor and preparation method therefor |
KR20190082194A (ko) * | 2017-12-25 | 2019-07-09 | 신파 파머슈티컬 컴퍼니 리미티드 | 아비박탐의 간단한 제조방법 |
KR102238179B1 (ko) | 2017-12-25 | 2021-04-09 | 신파 파머슈티컬 컴퍼니 리미티드 | 아비박탐의 간단한 제조방법 |
JP2020506160A (ja) * | 2017-12-25 | 2020-02-27 | 新発薬業有限公司 | アビバクタムの簡便な調製方法 |
WO2019127903A1 (zh) | 2017-12-25 | 2019-07-04 | 新发药业有限公司 | 一种阿维巴坦的简便制备方法 |
US11180500B2 (en) | 2018-10-01 | 2021-11-23 | Arixa Pharmaceuticals, Inc. | Derivatives of relebactam and uses thereof |
US11008321B2 (en) | 2019-03-12 | 2021-05-18 | Arixa Pharmaceuticals, Inc. | Crystalline form of an avibactam derivative |
US11565999B2 (en) | 2019-04-25 | 2023-01-31 | Arixa Pharmaceuticals, Inc. | Methods of synthesizing aztreonam derivatives |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6364431B2 (ja) | 光学活性なジアザビシクロオクタン誘導体およびその製造法 | |
US9284273B2 (en) | Compounds useful for producing an optically active diazabicyclooctane compound | |
Brinner et al. | A rapid and general method for the asymmetric synthesis of 2-substituted pyrrolidines using tert-butanesulfinamide | |
TWI438188B (zh) | 用於合成醫藥品之中間化合物的製造方法 | |
JP2019528254A (ja) | 改善された5r−ベンジルオキシアミノピペリジン−2s−ギ酸エステル及びそのシュウ酸塩の調製方法 | |
JP2000053642A (ja) | 3―アミノ―ピロリジン誘導体の製造方法 | |
TWI386395B (zh) | 哌啶衍生物的立體有擇合成 | |
AU2008267287B2 (en) | N5-(2-ethoxyethyl)-N3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors | |
JP2000319261A (ja) | キノロンカルボン酸類の製造方法 | |
CN110194731B (zh) | 巯基丙酰胺类化合物及其制备方法和药用用途 | |
JPWO2012070509A1 (ja) | 含窒素複素環の製造方法 | |
JP2006225344A (ja) | 2−アシルアミノメチル−3,4−ジヒドロキシピロリジン型酵素阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11850585 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2012549653 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2822758 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011346224 Country of ref document: AU Date of ref document: 20110630 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2011850585 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011850585 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20137018996 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013133870 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 238032 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 243939 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 244239 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 248246 Country of ref document: IL |